

# NATIONAL QUALITY FORUM

## Measure Submission and Evaluation Worksheet 5.0

This form contains the information submitted by measure developers/stewards, organized according to NQF's measure evaluation criteria and process. The evaluation criteria, evaluation guidance documents, and a blank online submission form are available on the [submitting standards web page](#).

NQF #: 1633	NQF Project: <a href="#">Renal Endorsement Maintenance 2011</a>
(for Endorsement Maintenance Review)	
Original Endorsement Date: Most Recent Endorsement Date:	
<b>BRIEF MEASURE INFORMATION</b>	
De.1 Measure Title: <a href="#">Blood Pressure Management</a>	
Co.1.1 Measure Steward: <a href="#">American Medical Association</a>	
De.2 Brief Description of Measure: <a href="#">Percentage of patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4 or 5, not receiving RRT) and proteinuria with a blood pressure &lt;130/80 mmHg OR &gt;= 130/80 mmHg with a documented plan of care</a>	
2a1.1 Numerator Statement: <a href="#">Patient visits with blood pressure &lt; 130/80 mmHg OR &gt;= 130/80 mmHg with a documented plan of care*</a>	
<p>Definitions:</p> <p>Plan of Care: *A documented plan of care should include one or more of the following: recheck blood pressure within 90 days; initiate or alter pharmacologic therapy for blood pressure control; initiate or alter non-pharmacologic therapy (lifestyle changes) for blood pressure control; documented review of patient's home blood pressure log which indicates that patient's blood pressure is or is not well controlled</p> <p>Numerator Instructions: <a href="#">If multiple blood pressure measurements are taken at a single visit, use the most recent measurement taken at that visit.</a></p> <p>The PCPI recommends that this measure be reported as follows:  <a href="#">% of patient visits meeting blood pressure &lt; 130/80 mmHg (component 1)</a>  <a href="#">% of patient visits meeting blood pressure &gt;= 130/80 mmHg with plan of care (component 2)</a>  <a href="#">% of patient visits meeting blood pressure &lt; 130/80 mmHg AND patient visits meeting blood pressure &gt;= 130/80 mmHg with plan of care (total measure score)</a></p>	
2a1.4 Denominator Statement: <a href="#">All patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4 or 5, not receiving RRT) and proteinuria</a>	
<p>Definitions:</p> <p>Proteinuria:</p> <ol style="list-style-type: none"> <li>1. <a href="#">&gt;300mg of albumin in the urine per 24 hours OR</a></li> <li>2. <a href="#">ACR &gt;300 mcg/mg creatinine OR</a></li> <li>3. <a href="#">Protein to creatinine ratio &gt; 0.3 mg/mg creatinine</a></li> </ol> <p>RRT (Renal Replacement Therapy)-<a href="#">For the purposes of this measure, RRT (Renal Replacement Therapy) includes hemodialysis, peritoneal dialysis, and kidney transplantation</a></p>	
2a1.8 Denominator Exclusions: <a href="#">None</a>	
1.1 Measure Type: <a href="#">Outcome</a>	

2a1. 25-26 Data Source: Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records  
 2a1.33 Level of Analysis: Clinician : Group/Practice, Clinician : Individual, Clinician : Team

1.2-1.4 Is this measure paired with another measure? No

De.3 If included in a composite, please identify the composite measure (title and NQF number if endorsed):  
 This measure is not a composite or paired measure.

**STAFF NOTES** (issues or questions regarding any criteria)

Comments on Conditions for Consideration:

Is the measure untested? Yes  No  If untested, explain how it meets criteria for consideration for time-limited endorsement:

1a. Specific national health goal/priority identified by DHHS or NPP addressed by the measure (check De.5):  
 5. Similar/related **endorsed** or submitted measures (check 5.1):  
 Other Criteria:

Staff Reviewer Name(s):

**1. IMPACT, OPPORTUNITY, EVIDENCE - IMPORTANCE TO MEASURE AND REPORT**

Importance to Measure and Report is a threshold criterion that must be met in order to recommend a measure for endorsement. All three subcriteria must be met to pass this criterion. See [guidance on evidence](#).  
**Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria. (evaluation criteria)**

1a. High Impact: H  M  L  I   
 (The measure directly addresses a specific national health goal/priority identified by DHHS or NPP, or some other high impact aspect of healthcare.)

De.4 Subject/Topic Areas (Check all the areas that apply): Renal, Renal : Chronic Kidney Disease (CKD)  
 De.5 Cross Cutting Areas (Check all the areas that apply):

1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, A leading cause of morbidity/mortality, Frequently performed procedure, High resource use, Patient/societal consequences of poor quality, Severity of illness

1a.2 If "Other," please describe:

1a.3 Summary of Evidence of High Impact (Provide epidemiologic or resource use data):  
 Chronic kidney disease (CKD), affects approximately 13.1% of United States adults and leads to end-stage renal disease (ESRD), cardiovascular disease (CVD), and premature death.(1)

CKD affects up to 5% of the population and 25% of those aged 70 years or older. An additional 6% of the population has signs of kidney damage, which may progress to ESRD.(2)

CKD is now recognized as a major public health concern. It is estimated that approximately 26.3 million adults in the U.S. have non-dialysis dependent kidney disease and over 470,000 have ESRD, collectively representing over 13% of the US population. In the next 20 years, the burden of CKD is expected to increase, with over 2 million individuals projected to be receiving renal replacement therapy (dialysis or kidney transplant) by 2030.(3)

CKD is a world-wide public health problem, with increasing incidence and prevalence, high cost, and poor outcomes. The major outcomes of CKD are loss of kidney function and development of cardiovascular disease (CVD). Increasing evidence indicates that the adverse outcomes of CKD can often be prevented or delayed through early detection and treatment (4).

Hypertension is both a cause and a complication of CKD; more than 50% to 75% of patients with CKD have blood pressure >140/90 mm Hg. In addition, hypertension is a risk factor for progression of kidney disease and for CVD. The goals of antihypertensive therapy in CKD are to lower blood pressure, reduce the risk of CVD, and slow progression of CKD (4).

Poorly controlled hypertension as either a cause or consequence of CKD predisposes to cardiovascular disease complications, as well as more rapid progression to ESRD.(5)

Currently, patients with CKD are five to 10 times more likely to die than to reach ESRD.(6)

Costs for CKD patients are now 23 percent of Medicare expenditures in the fee-for-service sector; when added to costs for ESRD patients, it appears that 31 percent of all Medicare expenditures are incurred by patients with a diagnosis of kidney disease.(7)

In 1993, costs for Medicare patients with CKD accounted for 3.8 percent of overall Medicare expenditures. By 2008, this had grown to 14.2 percent, in part reflecting growth in the number of recognized CKD patients.(7)

**1a.4 Citations for Evidence of High Impact cited in 1a.3:** 1. Snyder JJ, Collins AJ. Association of Preventive Health Care with Atherosclerotic Heart Disease and Mortality in CKD. *J Am Soc Nephrol.* 2009 July; 20(7): 1614–1622.

2. Alves TP, Lewis, J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. *Clinical Nephrology.*2010;74(1):S72-S77.

3. Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, et al. White/Black Racial Differences in Risk of End-Stage Renal Disease and Death. *Am J Med.* 2009 July;122(7):672-678.

4. National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* May;43(5 Suppl 1):S1-S290.

5. Duru OK, Li S, Jurkowitz C, Bakris G, et al. Race and Sex Differences in Hypertension Control in CKD: Results From the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis.* 2008 February;51(2):192-198.

6. Gilbertson DT, Liu J, Xue JL, Louis TA, et al. Projecting the Number of Patients with End-Stage Renal Disease in the United States to the Year 2015. *J Am Soc Nephrol* 16:3736-3741, 2005.

7. U S Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010.

**1b. Opportunity for Improvement:** H  M  L  I

*(There is a demonstrated performance gap - variability or overall less than optimal performance)*

**1b.1 Briefly explain the benefits (improvements in quality) envisioned by use of this measure:**

This measure is aimed at improving the number of patients with blood pressure controlled at < 130/80 mmHg. The plan of care component of the measure allows for patients to have blood pressure >= 130/80 mmHg with a plan of care in place. Accurate measurement in CKD is especially important, because hypertension is more common in CKD, and because JNC 7 identifies CKD as a "compelling indication" for more aggressive antihypertensive therapy because of the higher risk of CVD in CKD than in the general population (Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement. March 2010. AHRQ Publication No. 10-0058-EF. Agency for Healthcare Research and Quality, Rockville, MD). Hypertension is both a cause and a complication of CKD; more than 50% to 75% of patients with CKD have blood pressure > 140/90 mm Hg. In addition, hypertension is a risk factor for progression of kidney disease and for CVD. The goals of antihypertensive therapy in CKD are to lower blood pressure, reduce the risk of CVD, and slow progression of CKD (National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* May;43(5 Suppl 1):S1-S290).

**1b.2 Summary of Data Demonstrating Performance Gap** *(Variation or overall less than optimal performance across providers):*  
**[For Maintenance – Descriptive statistics for performance results for this measure - distribution of scores for measured entities by quartile/decile, mean, median, SD, min, max, etc.]**

We are continually reminded that in many patients with chronic kidney disease (CKD), blood pressure (BP) is not controlled to the target of < 130/80 mm Hg as recommended in most clinical practice guidelines. The Chronic Renal Insufficiency Cohort (CRIC) Study recruited 3,612 patients with an estimated glomerular filtration rate of 20-70 mL/min/1.73 m<sup>2</sup> (0.33-1.17 mL/min/1.73 m<sup>2</sup>) not on dialysis therapy. At the time of enrollment, the relevant BP target was achieved in only 46% of patients. This compares with 27% of individuals with an increased serum creatinine level in the Third National Health and Nutrition Examination Survey (NHANES III) and only 20.3% of patients with stage 3 CKD in the Kidney Early Evaluation Program.

This measure was used in the CMS Physician Quality Reporting Initiative, in the claims option (2008, 2009, 2010) as well as the Registry and Measure Group options (2009, 2010). The measure is also being used in the CMS Physician Quality Reporting System for 2011.

There is a gap in care as shown by this 2008 data; 43.2 % of patients reported on did not receive the optimal care.

10th percentile: 6.67 %

25th percentile: 25.76 %

50th percentile: 67.53 %

75th percentile: 92.54 %

90th percentile: 100 %

**1b.3 Citations for Data on Performance Gap:** [*For Maintenance* – Description of the data or sample for measure results reported in 1b.2 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]

Becker GJ, Wheeler DC. Blood Pressure Control in CKD Patients: Why Do We Fail to Implement the Guidelines? American Journal of Kidney Diseases, Vol 55, No 3 (March), 2010: pp 415-418.

Studies cited: the Chronic Renal Insufficiency Cohort (CRIC) Study (Muntner P, Anderson A, Charleston J, et al. Hypertension awareness, treatment, and control in adults with CKD.; results from the Chronic Renal Insufficiency Cohort (CRIC)

Study. Am J Kidney Dis. 2010;55(3):441-451), the Third National Health and Nutrition Examination Survey (NHANES III) (Peralta CA, Hicks LS, Chertow GM, et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005;45:1119-1124), and the Kidney Early Evaluation Program (KEEP) (Sarafidis PA, Li S, Chen SC, et al. Hypertension awareness, treatment, and control in chronic kidney disease. Am J Med. 2008;121:332-340.)

Confidential CMS PQRI 2008 Performance Information by Measure. Jan-Sept TAP file.

**1b.4 Summary of Data on Disparities by Population Group:** [*For Maintenance* –Descriptive statistics for performance results for this measure by population group]

African-Americans have the highest reported prevalence and incidence of treated ESRD. Overall, African-Americans are four times more likely to progress to ESRD compared to whites (988 vs. 254 patients per million) and at a higher-than-average risk for developing ESRD in the Southeastern US. Diabetes Mellitus (DM) is the leading cause of ESRD in all racial and ethnic groups, but occurs at a much higher rate among African-Americans, Hispanics and Native Americans (422,382.9, and 307.2 vs. 115 per million, respectively) compared to whites.

In addition, African-Americans have the highest rate of hypertension-related ESRD, which far exceeds other racial and ethnic groups. As a result, hypertension remains a close second to DM as the leading cause of ESRD in the African-American community (1).

In individuals with early CKD, African American women (odds ratio [OR], 1.47; 95% confidence interval [CI], 1.14 to 1.88), white men (OR, 1.85; 95% CI, 1.39 to 2.46), and white women (OR, 1.69; 95% CI, 1.28 to 2.22) had greater odds of hypertension control (blood pressure <130/80 mm Hg) than African American men. In individuals with late CKD, white men (OR, 1.66; 95% CI, 1.10 to 2.52) and white women (OR, 1.67; 95% CI, 1.13 to 2.46) had greater odds of hypertension control than African American men. No differences were seen between African American men and women with late CKD (2).

In the United States, the incidence of ESRD from hypertensive CKD in African American men is 5 times that in white men and 1.4 times that in African American women(2).

**1b.5 Citations for Data on Disparities Cited in 1b.4:** [*For Maintenance* – Description of the data or sample for measure results reported in 1b.4 including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included]

1. Alves TP, Lewis, J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. *Clinical Nephrology*.2010;74(1):S72-S77.
2. Duru OK, Li S, Jurkovicz C, Bakris G, et al. Race and Sex Differences in Hypertension Control in CKD: Results From the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis*. 2008 February;51(2):192-198.

1c. Evidence (*Measure focus is a health outcome OR meets the criteria for quantity, quality, consistency of the body of evidence.*)  
 Is the measure focus a health outcome? Yes  No  **If not a health outcome**, rate the body of evidence.

Quantity: H  M  L  I  Quality: H  M  L  I  Consistency: H  M  L  I

Quantity	Quality	Consistency	Does the measure pass subcriterion1c?
M-H	M-H	M-H	Yes <input type="checkbox"/>
L	M-H	M	Yes <input type="checkbox"/> IF additional research unlikely to change conclusion that benefits to patients outweigh harms: otherwise No <input type="checkbox"/>
M-H	L	M-H	Yes <input type="checkbox"/> IF potential benefits to patients clearly outweigh potential harms: otherwise No <input type="checkbox"/>
L-M-H	L-M-H	L	No <input type="checkbox"/>

Health outcome – rationale supports relationship to at least one healthcare structure, process, intervention, or service	Does the measure pass subcriterion1c? Yes <input type="checkbox"/> IF rationale supports relationship
--	--

1c.1 **Structure-Process-Outcome Relationship** (*Briefly state the measure focus, e.g., health outcome, intermediate clinical outcome, process, structure; then identify the appropriate links, e.g., structure-process-health outcome; process- health outcome; intermediate clinical outcome-health outcome*):

The intent of this measure is to manage the blood pressure of patients with chronic kidney disease by either confirming that blood pressure is controlled at <130/80 or documenting a plan of care for treatment of blood pressure that is 130/80 mmHg or higher. The plan of care should include one or more of the following: rechecking the blood pressure within 90 days, initiating or alternating pharmacologic therapy for blood pressure control, initiating or altering non-pharmacologic therapy through lifestyle changes for blood pressure control, and/or documenting a review of the patient’s home blood pressure log which would indicate that the patient’s blood pressure is or is not well controlled. The plan of care is a process component of the measure that serves as an alternative to the intermediate outcome, which is documentation of the patients that have blood pressure less than 130/80. This measure is, therefore, a combined process and intermediate outcome measure, which is then linked to several health outcomes. The management of blood pressure is linked to slowing the progression of kidney disease, which will also decrease the incidence of cardiovascular disease, an associated illness.

1c.2-3 **Type of Evidence** (*Check all that apply*):  
 Clinical Practice Guideline

1c.4 **Directness of Evidence to the Specified Measure** (*State the central topic, population, and outcomes addressed in the body of evidence and identify any differences from the measure focus and measure target population*):

The guidelines supporting this measure are focused on hypertension and antihypertensive agents in chronic kidney disease. The guidelines focus on the adult CKD population but also include special considerations for the pediatric CKD population. This measure specifically focuses on stages 3, 4, and 5 CKD patients that are not receiving renal replacement therapy. The measure also includes patients that have proteinuria, and is therefore, more specific, with regards to the patient population. Proteinuria, which includes the measurement of all proteins in the urine versus only albuminuria, is discussed in the guidelines with regards to therapy and improved outcomes for CKD patients. The requirement for proteinuria in the denominator for these measures is based on growing controversy regarding the appropriateness of prior recommendations for a BP <130/80 and for the use of ACE inhibition/angiotensin receptor blockade in non-proteinuric kidney disease (Chang TI, Cheung AK, Chertow GM. Blood pressure control in type 2 diabetes mellitus. *Am J Kidney Dis* 2010; 56: 1029-1031 & Agarwal R. Blood pressure goal in chronic kidney disease: what is the evidence? *Current Opinion in Nephrology & Hypertension* 2011; 20:229–232).

The evidence cited in support of the measure, demonstrates the association between patients with chronic kidney disease and hypertension. The guideline recommendations state that patients with CKD should be considered in the "highest risk" group for

cardiovascular disease, and that the target blood pressure for CVD risk reduction in CKD should be <130/80 mmHg. The measure numerator captures the patient visits with blood pressure <130/80 mmHg OR > or = 130/80 mmHg with a documented plan of care. The plan of care should include one or more of the following: rechecking the blood pressure within 90 days, initiating or alternating pharmacologic therapy for blood pressure control, initiating or altering non-pharmacologic therapy through lifestyle changes for blood pressure control, and/or documenting a review of the patient's home blood pressure log which would indicate that the patient's blood pressure is or is not well controlled. Guideline recommendation statements that support the plan of care include: elevated blood pressure must be confirmed on repeated visits before characterizing an individual as having hypertension, all classes of antihypertensive agents are effective in lowering blood pressure in CKD, lifestyle modifications recommended for CVD risk reduction should be recommended as part of the treatment regimen, and patients should be taught to measure and record their blood pressure, whenever possible.

There are few studies on the treatment of hypertension in CKD. Most of the largest clinical studies in patients with CKD were designed to evaluate the efficacy of therapy in slowing the progression of CKD rather than reducing risk of CVD. Therefore, most of the recommendations in this guideline are extrapolated from clinical studies performed in the general population.

**1c.5 Quantity of Studies in the Body of Evidence** (*Total number of studies, not articles*): Overall, for K/DOQI's clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, 11,688 abstracts were screened by the Evidence Review Team, 899 articles were retrieved and reviewed, and data were extracted from 177 articles. Forty-seven articles were added by the Work Group. Finally, results from 76 articles were systematically included in the guideline. The total number of studies reviewed was not specified.

There are few controlled trials comparing levels of blood pressure or classes of antihypertensive agents to reduce CVD risk in CKD. Thus, the Work Group extrapolated from guidelines of high-risk patients in the general population. The Work Group was convened in 2001, after the release of JNC 6 but prior to the release of JNC 7 in May 2003. The Work Group elected to review recommendations in JNC 6, as well as other guidelines for the treatment of hypertension and CVD that were published since JNC 6. Guidelines were identified by a review of guidelines listed in the National Guideline Clearinghouse ([www.guideline.gov](http://www.guideline.gov)). A total of 21 guidelines were retrieved, of which 5 were found not to be relevant for this review.

During the Work Group's deliberations, results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) were reported, and JNC 7 was released. Some members of the Work Group (A.S.L. and M.V.R.) were able to review data from a subgroup of ALLHAT participants with CKD (defined as estimated GFR <60 mL/min/1.73 m<sup>2</sup>), which was later reported in abstract form. Thus, the Work Group also relied on evidence contained in the ALLHAT report, the ALLHAT CKD subgroup, some of the key clinical trials included in JNC 7, as well as recommendations of JNC 7. Clinical trials in the general population were abstracted or compiled in evidence tables.

National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis.* May;43(5 Suppl 1):S1-S290.

**1c.6 Quality of Body of Evidence** (*Summarize the certainty or confidence in the estimates of benefits and harms to patients across studies in the body of evidence resulting from study factors. Please address: a) study design/flaws; b) directness/indirectness of the evidence to this measure (e.g., interventions, comparisons, outcomes assessed, population included in the evidence); and c) imprecision/wide confidence intervals due to few patients or events*): Patients with CKD should be considered in the "highest-risk" group for CVD for implementing recommendations for pharmacological therapy, irrespective of cause of CKD (Strong). This recommendation is "Strong," indicating that the evidence includes results from well-designed, well-conducted study/studies in the target population that directly assess effects on health outcomes. Patients with CKD have rates of CVD that are 5 to 500 times higher than age- and sex-matched controls in the general population. Thus, it is of the utmost importance to reduce the risk of CVD in patients with CKD.

Target blood pressure for CVD risk reduction in CKD should be <130/80 mm Hg (Moderately Strong). This recommendation is "Moderately Strong," indicating that the evidence is sufficient to determine effects on health outcomes in the target population, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; OR evidence is from a population other than the target population, but from well-designed, well-conducted studies; OR evidence is from studies with some problems in design and/or analysis; OR evidence is from well-designed, well-conducted studies on surrogate endpoints for efficacy and/or safety in the target population. Numerous epidemiological studies show a graded, independent, and strong relationship

between the level of arterial blood pressure and CVD. Above a SBP of 115 mm Hg, and above a DBP of 75 mm Hg, the risk of CVD doubles with each increment of SBP of 20 mm Hg or DBP of 10 mm Hg. In persons over age 50, SBP greater than 140 mm Hg is a critical and more important CVD risk factor than DBP.

Controlled trials in essential hypertension conclusively show a beneficial effect of lowering blood pressure to <140/90 mm Hg. Controlled trials in high-risk individuals with diabetes or heart failure suggest beneficial effects of reduction of blood pressure to even lower values. Based on these studies, and on observational studies, a number of guidelines for patients with either diabetes mellitus or congestive heart failure recommend a goal blood pressure of <130/80 mm Hg.

There are few studies regarding blood pressure goals for CVD risk reduction in patients with CKD. Thus, the Work Group elected to extrapolate the recommendations for high-risk patients to patients with CKD. Based on a summary of guidelines, the Work Group recommends to reduce the risk of CVD in CKD are an SBP <130 mm Hg and a DBP <80 mm Hg. In certain select cases, it may be appropriate to maintain a blood pressure higher than the recommended goal of <130/80 mm Hg. These conditions include orthostatic hypotension, postprandial hypotension, autonomic dysfunction, and severe peripheral vascular disease that is exacerbated by a blood pressure less than 130/80 mm Hg.

Controlled trials evaluating lifestyle modifications for blood pressure management in CKD are limited. For this guideline, recommendations for high blood pressure and other conditions were integrated with recommendations for CKD. Dietary and lifestyle modifications are recommended in the general population for reduction of CVD risk (Strong). Prospective cohort studies and controlled trials have identified specific dietary patterns that are effective at reducing the risk of CVD. Diets that include nonhydrogenated, unsaturated fats as the predominant form of dietary fat appear to provide the most protection against coronary heart disease. Diets that include whole grains as the main form of carbohydrates, an abundance of fruits and vegetables, and adequate omega-3 fatty acids also offer significant protection. It has been proposed that such diets—together with regular physical activity, avoidance of smoking, and maintaining a healthy weight—could prevent the majority of CVD in adults. The beneficial effects of diet on traditional CVD risk factors, including lipid reduction, prevention of diabetes, and blood pressure reduction, may account for most of the overall CVD risk reduction.

Dietary and lifestyle modifications are recommended for prevention and treatment of high blood pressure in the general population (Strong). JNC 7 recommends lifestyle modifications as initial therapy in newly diagnosed hypertensive patients and as adjuvant therapy in persons on medications. Apart from physical activity, most lifestyle recommendations are nutrition-based and include (1) reduction of dietary sodium consumption to <100 mmol/d (2.4 g/d); (2) weight loss (for overweight and obese persons) and weight control (for nonoverweight); (3) moderation of alcohol intake (<=2 drinks per day for men and <=1 drink/day for women); and (4) adoption of the Dietary Approaches to Stop Hypertension (DASH) diet.

Studies reviewed for Guideline 3 (Measurement of Blood Pressure in Adults) included authoritative reviews, including JNC 6 and JNC 7; a meta-analysis conducted for AHRQ National High Blood Pressure Educational Program (NHBPEP)/National Heart, Lung and Blood Institute, and American Heart Association (AHA) Working Meeting on Blood Pressure Measurement 2003 and its summary report; AHA recommendations for indirect measurement of arterial blood pressure, European Society of Hypertension recommendations for conventional, ambulatory, and home blood pressure measurement; and an international conference on ABPM in 2001. More detailed information about blood pressure measurement techniques can be found in these reports.

Accurate measurement of blood pressure is important for detection, evaluation, and treatment of hypertension (Strong). JNC 7 provides a new, simplified classification of hypertension severity for adults aged 18 years and older. The classification is based on the average of two or more properly measured seated blood pressure readings on each of two or more office visits. When SBP and DBP fall into different categories, the higher category should be selected to classify the individual. Accurate measurement in CKD is especially important, because hypertension is more common in CKD, and because JNC 7 identifies CKD as a "compelling indication" for more aggressive antihypertensive therapy because of the higher risk of CVD in CKD than in the general population.

#### LIMITATIONS:

There are few studies on the treatment of hypertension in CKD. Most of the largest clinical studies in patients with CKD were designed to evaluate the efficacy of therapy in slowing the progression of CKD rather than reducing risk of CVD. Therefore, most of the recommendations in this guideline are extrapolated from clinical studies performed in the general population.

Reference: National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in

chronic kidney disease. Am J Kidney Dis. May;43(5 Suppl 1):S1-S290.

**1c.7 Consistency of Results across Studies** (*Summarize the consistency of the magnitude and direction of the effect*): Target blood pressure for CVD risk reduction in CKD should be <130/80 mm Hg (Moderately Strong). Numerous epidemiological studies show a graded, independent, and strong relationship between the level of arterial blood pressure and CVD. Above a SBP of 115 mm Hg, and above a DBP of 75 mm Hg, the risk of CVD doubles with each increment of SBP of 20 mm Hg or DBP of 10 mm Hg. In persons over age 50, SBP greater than 140 mm Hg is a critical and more important CVD risk factor than DBP.

Controlled trials in essential hypertension conclusively show a beneficial effect of lowering blood pressure to <140/90 mm Hg. Controlled trials in high-risk individuals with diabetes or heart failure suggest beneficial effects of reduction of blood pressure to even lower values. Based on these studies, and on observational studies, a number of guidelines for patients with either diabetes mellitus or congestive heart failure recommend a goal blood pressure of <130/80 mm Hg.

There are few studies regarding blood pressure goals for CVD risk reduction in patients with CKD. Thus, the Work Group elected to extrapolate the recommendations for high-risk patients to patients with CKD. Based on a summary of guidelines, the Work Group recommends to reduce the risk of CVD in CKD are an SBP <130 mm Hg and a DBP <80 mm Hg. In certain select cases, it may be appropriate to maintain a blood pressure higher than the recommended goal of <130/80 mm Hg. These conditions include orthostatic hypotension, postprandial hypotension, autonomic dysfunction, and severe peripheral vascular disease that is exacerbated by a blood pressure less than 130/80 mm Hg. Based on studies of the relationship of SBP and kidney disease outcomes reviewed in Guidelines 8 and 9, the Work Group recommended caution in lowering SBP <110 mm Hg and more frequent monitoring in patients treated with antihypertensive agents and SBP <120 mm Hg.

Reference: National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. May;43(5 Suppl 1):S1-S290.

**1c.8 Net Benefit** (*Provide estimates of effect for benefit/outcome; identify harms addressed and estimates of effect; and net benefit - benefit over harms*):

In certain select cases, it may be appropriate to maintain a blood pressure higher than the recommended goal of <130/80 mm Hg. These conditions include orthostatic hypotension, postprandial hypotension, autonomic dysfunction, and severe peripheral vascular disease that is exacerbated by a blood pressure less than 130/80 mm Hg. Based on studies of the relationship of SBP and kidney disease outcomes reviewed in Guidelines 8 and 9, the Work Group recommended caution in lowering SBP <110 mm Hg and more frequent monitoring in patients treated with antihypertensive agents and SBP <120 mm Hg.

Numerous epidemiological studies show a graded, independent, and strong relationship between the level of arterial blood pressure and CVD. Controlled trials in essential hypertension conclusively show a beneficial effect of lowering blood pressure to <140/90 mm Hg. Controlled trials in high-risk individuals with diabetes or heart failure suggest beneficial effects of reduction of blood pressure to even lower values. Based on these studies, and on observational studies, a number of guidelines for patients with either diabetes mellitus or congestive heart failure recommend a goal blood pressure of <130/80 mm Hg.

The control of hypertension in the individual patient clearly involves difficulties of measurement and response to treatment. These are reflected in the statistical description of any given patient population, which is the currency of reporting clinical outcomes at facility/practice level. Systolic blood pressure values follow an approximately Gaussian distribution in most populations, with standard deviations (SD) that are typically 15 mm Hg or more. Because of the variability of values and a relatively fixed dispersion of blood pressure levels, a high rate of adherence to guidelines must necessarily involve mean/median population values well below the desired goal. The percentage achievement of goal blood pressure level depends on these outcome distributions for any patient population. Therefore, the lower the mean, the higher the percent adherence rate.

Reference: National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. May;43(5 Suppl 1):S1-S290.

**1c.9 Grading of Strength/Quality of the Body of Evidence.** Has the body of evidence been graded? **Yes**

**1c.10 If body of evidence graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:** The [Guideline Development] Work Group was convened by the NKF Kidney Disease Outcomes



Quality Initiative (KDOQI) in response to recommendations of the NKF Task Force on CVD in Chronic Renal Disease. The Co-Chairs of the KDOQI Advisory Board selected the Work Group Chair and Director of the Evidence Review Team, who then assembled groups responsible for the development of the guidelines and the evidence report, respectively. The Work Group and Evidence Review Team collaborated closely throughout the project.

The Work Group consisted of "domain experts," including individuals with expertise in adult and pediatric nephrology, cardiology, epidemiology, nutrition, social work, and family medicine. In addition, the Work Group had liaison members from the National Institute of Diabetes, Digestive and Kidney Diseases, from the National Heart Lung and Blood Institute and from the Renal Physicians Association. The Work Group also maintained communication with members of JNC 7 and ADA 2003 and with investigators of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) for which results were announced during the time the Work Groups held meetings. The Evidence Review Team consisted of nephrologists and methodologists from Tufts-New England Medical Center and elsewhere with expertise in systematic review of the medical literature.

Work Group Membership:

Chair:

Andrew S. Levey, MD  
Tufts-New England Medical Center  
Boston, MA

Vice-Chair:

Michael V. Rocco, MD, MS  
Wake Forest University School of Medicine  
Winston Salem, NC

Sharon Anderson, MD  
Oregon Health and Science University  
Portland, OR

Sharon P. Andreoli, MD  
Wells Research Center  
Indiana University Medical Center  
Indianapolis, IN

George R. Bailie, PharmD, PhD  
Albany College of Pharmacy  
Albany, NY

George L. Bakris, MD  
Rush Presbyterian St. Luke's Medical Center  
Chicago, IL

Mary Beth Callahan, ACSW, LMSW, ACP  
Dallas Transplant Institute  
Dallas, TX

Jane H. Greene, RD, CSR  
Vanderbilt University  
Nashville, TN

Cynda Ann Johnson, MD, MBA  
Brody School of Medicine  
East Carolina University  
Greenville, NC

James P. Lash, MD  
University of Illinois  
Chicago, IL

Peter A. McCullough, MD, MPH  
William Beaumont Hospital,  
Beaumont Health Center  
Royal Oaks, MI

Edgar R. Miller III, MD, PhD  
Johns Hopkins Medical Institutions  
Baltimore, MD

Joseph V. Nally, MD  
Cleveland Clinic Foundation  
Cleveland, OH

John D. Pirsch, MD  
University of Wisconsin Hospital & Clinic  
Madison, WI

Ronald J. Portman, MD  
University of Texas  
Houston, TX

Mary Ann Sevick, RN, ScD  
Department of Health & Community Systems  
School of Nursing  
University of Pittsburgh  
Pittsburgh, PA

Domenic Sica, MD  
Virginia Commonwealth University Health Systems  
Richmond, VA

Donald E. Wesson, MD  
Texas Tech University Health Science Center  
Lubbock, TX

Liaison Members:

Lawrence Agodoa, MD  
National Institutes of Health  
NIDDK  
Silver Springs, MD Jeffrey A. Cutler, MD, MPH  
National Institutes of Health  
NHLBI  
Bethesda, MD  
Kline Bolton, MD (RPA)  
University of Virginia Hospital  
Charlottesville, VA Tom Hostetter, MD  
National Institutes of Health  
NIDDK  
Bethesda, MD

Evidence Review Team:  
Joseph Lau, MD, Director  
Tufts-New England Medical Center  
Boston, MA

Katrin Uhlig, MD, Assistant Director  
Tufts-New England Medical Center  
Boston, MA

Priscilla Chew, MPH  
Annamaria Kausz, MD, MS  
Bruce Kupelnick, BA  
Gowri Raman, MD  
Mark Sarnak, MD  
Chenchen Wang, MD, MSc  
Tufts-New England Medical Center  
Boston, MA

Brad C. Astor, PhD, MPH  
Johns Hopkins University  
Baltimore, MD

All work group members completed a disclosure statement certifying that any potential conflict of interest would not influence their judgment or actions concerning the KDOQI.

**1c.11 System Used for Grading the Body of Evidence:** Other

**1c.12 If other, identify and describe the grading scale with definitions:** The strength of evidence was graded using a rating system that takes into account: (1) methodological quality of the studies; (2) whether or not the study was carried out in the target population, ie, patients with CKD, or in other populations; and (3) whether the studies examined health outcomes directly, or examined surrogate measures for those outcomes, eg, reducing proteinuria rather than slowing progression of CKD. These three separate study characteristics were combined in rating the strength of a body of evidence provided by the composite of the pertinent studies.

Strong-Evidence includes results from well-designed, well-conducted study/studies in the target population that directly assess effects on health outcomes

Moderately strong-Evidence is sufficient to determine effects on health outcomes in the target population, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; OR evidence is from a population other than the target population, but from well-designed, well-conducted studies; OR evidence is from studies with some problems in design and/or analysis; OR evidence is from well-designed, well-conducted studies on surrogate endpoints for efficacy and/or safety in the target population.

Weak-Evidence is insufficient to assess the effects on net health outcomes because it is from studies with some problems in design and/or analysis on surrogate endpoints for efficacy and/or safety in the target population; OR the evidence is only for surrogate measures in a population other than the target population; OR the evidence is from studies that are poorly designed and/or analyzed.

**1c.13 Grade Assigned to the Body of Evidence:** Strong, Moderately Strong

**1c.14 Summary of Controversy/Contradictory Evidence:** In certain select cases, it may be appropriate to maintain a blood pressure higher than the recommended goal of <130/80 mm Hg. These conditions include orthostatic hypotension, postprandial hypotension, autonomic dysfunction, and severe peripheral vascular disease that is exacerbated by a blood pressure less than

130/80 mm Hg. Based on studies of the relationship of SBP and kidney disease outcomes reviewed in Guidelines 8 and 9, the [Guideline Development] Work Group recommended caution in lowering SBP <110 mm Hg and more frequent monitoring in patients treated with antihypertensive agents and SBP <120 mm Hg.

Reference: National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. May;43(5 Suppl 1):S1-S290.

**1c.15 Citations for Evidence other than Guidelines (Guidelines addressed below):**

Not applicable.

**1c.16 Quote verbatim, the specific guideline recommendation (Including guideline # and/or page #):**

Patients with CKD should be considered in the "highest-risk" group for CVD for implementing recommendations for pharmacological therapy, irrespective of cause of CKD (Grade A) (Guideline 7)

Target blood pressure for CVD risk reduction in CKD and diabetic/nondiabetic kidney disease should be <130/80 mmHg (Grade B)(Guideline 7)

All classes of antihypertensive agents are effective in lowering blood pressure in CKD. Antihypertensive agents should be prescribed as follows, when possible: Preferred agents for CKD should be used first (Grade A); Diuretics should be included in the antihypertensive regimen in most patients (Grade A); Choose additional agents based on cardiovascular disease-specific indications to achieve therapeutic and preventive targets and to avoid side-effects and interactions (Grade B) (Guideline 7)

Lifestyle modifications recommended for CVD risk reduction should be recommended as part of the treatment regimen (Grade B) (Guideline 6)

Elevated blood pressure must be confirmed on repeated visits before characterizing an individual as having hypertension. Blood pressure can be determined by resting blood pressure measurement in the health-care provider's office (casual blood pressure [CBP]), self-measured blood pressure (SMBP), or ambulatory blood pressure monitoring (ABPM). Blood pressure should be measured according to the recommendations for indirect measurement of arterial blood pressure of the American Heart Association and Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) (Grade A); Patients should be taught to measure and record their blood pressure, whenever possible (Grade C) (Guideline 3)

**1c.17 Clinical Practice Guideline Citation:** National Kidney Foundation. (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. May;43(5 Suppl 1):S1-S290.

**1c.18 National Guideline Clearinghouse or other URL:** [http://www.kidney.org/professionals/KDOQI/guidelines\\_bp/index.htm](http://www.kidney.org/professionals/KDOQI/guidelines_bp/index.htm)

**1c.19 Grading of Strength of Guideline Recommendation.** Has the recommendation been graded? Yes

**1c.20 If guideline recommendation graded, identify the entity that graded the evidence including balance of representation and any disclosures regarding bias:** The [Guideline Development] Work Group was convened by the NKF Kidney Disease Outcomes Quality Initiative (KDOQI) in response to recommendations of the NKF Task Force on CVD in Chronic Renal Disease. The Co-Chairs of the KDOQI Advisory Board selected the Work Group Chair and Director of the Evidence Review Team, who then assembled groups responsible for the development of the guidelines and the evidence report, respectively. The Work Group and Evidence Review Team collaborated closely throughout the project. The Work Group consisted of "domain experts," including individuals with expertise in adult and pediatric nephrology, cardiology, epidemiology, nutrition, social work, and family medicine. In addition, the Work Group had liaison members from the National Institute of Diabetes, Digestive and Kidney Diseases, from the National Heart Lung and Blood Institute and from the Renal Physicians Association. The Work Group also maintained communication with members of JNC 7 and ADA 2003 and with investigators of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) for which results were announced during the time the Work Groups held meetings. The Evidence Review Team consisted of nephrologists and methodologists from Tufts-New England Medical Center and elsewhere with expertise in systematic review of the medical literature. All work group members completed a disclosure statement certifying that any potential conflict of interest would not influence their judgment or actions concerning the KDOQI. Work Group and Evidence

Review Team members are listed in 1c.10.

1c.21 System Used for Grading the Strength of Guideline Recommendation: **Other**

1c.22 If other, identify and describe the grading scale with definitions: The overall strength of each guideline statement was rated by assigning either "A," "B," or "C."

Grade A-It is strongly recommended that clinicians routinely follow the guideline for eligible patients. There is strong evidence that the practice improves health outcomes

Grade B-It is recommended that clinicians routinely follow the guideline for eligible patients. There is moderately strong evidence that the practice improves health outcomes.

Grade C-It is recommended that clinicians consider following the guideline for eligible patients. This recommendation is based on either weak evidence or on the opinions of the Work Group and reviewers, that the practice might improve health outcomes.

1c.23 Grade Assigned to the Recommendation: Recommendation 1: Grade A; Recommendation 2: Grade B; Recommendation 3: Grades A, B; Recommendation 4: Grade B; Recommendation 5: Grades A, C

1c.24 Rationale for Using this Guideline Over Others: It is the PCPI policy to use guidelines, which are evidence-based, applicable to physicians and other health-care providers, and developed by a national specialty organization or government agency. In addition, the PCPI has now expanded what is acceptable as the evidence base for measures to include documented quality improvement (QI) initiatives or implementation projects that have demonstrated improvement in quality of care.

KDOQI was founded on the principles of structured review of the literature, with data abstraction of pertinent articles. All of the KDOQI guidelines were developed in this manner. Since the first guideline was published, additional refinement and maturation of this process has occurred. This rigorous process of guideline development has been well received as both credible and transparent.

National Kidney Foundation. KDOQI Guideline Processed. [http://www.kidney.org/professionals/KDOQI/guidelines\\_process.cfm](http://www.kidney.org/professionals/KDOQI/guidelines_process.cfm). Accessed: May 19, 2011.

Based on the NQF descriptions for rating the evidence, what was the developer's assessment of the quantity, quality, and consistency of the body of evidence?

1c.25 Quantity: **Moderate** 1c.26 Quality: **Moderate** 1c.27 Consistency: **Moderate**

Was the threshold criterion, *Importance to Measure and Report*, met?

(1a & 1b must be rated moderate or high and 1c yes) Yes  No

Provide rationale based on specific subcriteria:

**For a new measure if the Committee votes NO, then STOP.**

**For a measure undergoing endorsement maintenance, if the Committee votes NO because of 1b. (no opportunity for improvement), it may be considered for continued endorsement and all criteria need to be evaluated.**

## 2. RELIABILITY & VALIDITY - SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (**evaluation criteria**)

Measure testing must demonstrate adequate reliability and validity in order to be recommended for endorsement. Testing may be conducted for data elements and/or the computed measure score. Testing information and results should be entered in the appropriate field. Supplemental materials may be referenced or attached in item 2.1. See [guidance on measure testing](#).

S.1 Measure Web Page (In the future, NQF will require measure stewards to provide a URL link to a web page where current detailed specifications can be obtained). Do you have a web page where current detailed specifications for this measure can be obtained? **Yes**

S.2 If yes, provide web page URL: [physicianconsortium.org](http://physicianconsortium.org)

2a. RELIABILITY. Precise Specifications and Reliability Testing: H  M  L  I

2a1. Precise Measure Specifications. (*The measure specifications precise and unambiguous.*)

2a1.1 Numerator Statement (*Brief, narrative description of the measure focus or what is being measured about the target population, e.g., cases from the target population with the target process, condition, event, or outcome*):

Patient visits with blood pressure < 130/80 mmHg OR >= 130/80 mmHg with a documented plan of care\*

Definitions:

Plan of Care: \*A documented plan of care should include one or more of the following: recheck blood pressure within 90 days; initiate or alter pharmacologic therapy for blood pressure control; initiate or alter non-pharmacologic therapy (lifestyle changes) for blood pressure control; documented review of patient's home blood pressure log which indicates that patient's blood pressure is or is not well controlled

Numerator Instructions: If multiple blood pressure measurements are taken at a single visit, use the most recent measurement taken at that visit.

The PCPI recommends that this measure be reported as follows:

% of patient visits meeting blood pressure < 130/80 mmHg (component 1)

% of patient visits meeting blood pressure >= 130/80 mmHg with plan of care (component 2)

% of patient visits meeting blood pressure < 130/80 mmHg AND patient visits meeting blood pressure >= 130/80 mmHg with plan of care (total measure score)

2a1.2 Numerator Time Window (*The time period in which the target process, condition, event, or outcome is eligible for inclusion*):

Once during the measurement period

2a1.3 Numerator Details (*All information required to identify and calculate the cases from the target population with the target process, condition, event, or outcome such as definitions, codes with descriptors, and/or specific data collection items/responses*):

See attached for EHR specifications.

For Claims/Administrative:

Report one CPT Category II codes for systolic blood pressure:

3074F – Most recent systolic blood pressure <130 mmHg

3075F – Most recent systolic blood pressure 130 mmHg to 139 mmHg

3077F – Most recent systolic blood pressure >=140 mmHg

AND

Report one CPT Category II codes for diastolic blood pressure

3078F – Most recent diastolic blood pressure <80 mmHg

3079F – Most recent diastolic blood pressure 80 mmHg to 89 mmHg

3080F – Most recent diastolic blood pressure >=90 mmHg

AND (if systolic blood pressure >= 130 mmHg OR diastolic blood pressure is >= 80 mmHg)

Report CPT Category II code 0513F – Elevated blood pressure plan of care documented

2a1.4 Denominator Statement (*Brief, narrative description of the target population being measured*):

All patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4 or 5, not receiving RRT) and proteinuria

Definitions:

Proteinuria:

1. >300mg of albumin in the urine per 24 hours OR

2. ACR >300 mcg/mg creatinine OR

3. Protein to creatinine ratio > 0.3 mg/mg creatinine

RRT (Renal Replacement Therapy)-For the purposes of this measure, RRT (Renal Replacement Therapy) includes hemodialysis, peritoneal dialysis, and kidney transplantation

2a1.5 Target Population Category (Check all the populations for which the measure is specified and tested if any): [Adult/Elderly Care](#)

2a1.6 Denominator Time Window (The time period in which cases are eligible for inclusion):  
12 consecutive months

2a1.7 Denominator Details (All information required to identify and calculate the target population/denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):

See attached for EHR specifications.

For Claims/Administrative: See coding tables attached for coding (ICD-9-CM, ICD-10-CM, CPT)

2a1.8 Denominator Exclusions (Brief narrative description of exclusions from the target population):  
None

2a1.9 Denominator Exclusion Details (All information required to identify and calculate exclusions from the denominator such as definitions, codes with descriptors, and/or specific data collection items/responses):

None

2a1.10 Stratification Details/Variables (All information required to stratify the measure results including the stratification variables, codes with descriptors, definitions, and/or specific data collection items/responses):

We encourage the results of this measure to be stratified by race, ethnicity, primary language, and gender, and have included these variables as recommended data elements to be collected.

2a1.11 Risk Adjustment Type (Select type. Provide specifications for risk stratification in 2a1.10 and for statistical model in 2a1.13): No risk adjustment or risk stratification    2a1.12 If "Other," please describe:

2a1.13 Statistical Risk Model and Variables (Name the statistical method - e.g., logistic regression and list all the risk factor variables. Note - risk model development should be addressed in 2b4.):

This measure is not risk adjusted.

2a1.14-16 Detailed Risk Model Available at Web page URL (or attachment). Include coefficients, equations, codes with descriptors, definitions, and/or specific data collection items/responses. Attach documents only if they are not available on a webpage and keep attached file to 5 MB or less. NQF strongly prefers you make documents available at a Web page URL. Please supply login/password if needed:

2a1.17-18. Type of Score: [Rate/proportion](#)

2a1.19 Interpretation of Score (Classifies interpretation of score according to whether better quality is associated with a higher score, a lower score, a score falling within a defined interval, or a passing score): [Better quality = Higher score](#)

2a1.20 Calculation Algorithm/Measure Logic (Describe the calculation of the measure score as an ordered sequence of steps including identifying the target population; exclusions; cases meeting the target process, condition, event, or outcome; aggregating data; risk adjustment; etc.):

Calculation algorithm is included in data dictionary/code table attachment (2a1.30).

2a1.21-23 Calculation Algorithm/Measure Logic Diagram URL or attachment:

2a1.24 **Sampling (Survey) Methodology.** If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate):  
 Our measure does not require sampling or a survey.

2a1.25 **Data Source** (Check all the sources for which the measure is specified and tested). If other, please describe:  
 Administrative claims, Electronic Clinical Data, Electronic Clinical Data : Electronic Health Record, Electronic Clinical Data : Registry, Paper Records

2a1.26 **Data Source/Data Collection Instrument** (Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.): N/A

2a1.27-29 Data Source/data Collection Instrument Reference Web Page URL or Attachment:

2a1.30-32 Data Dictionary/Code Table Web Page URL or Attachment:

Attachment  
[AMA-PCPI\\_AKID-1\\_BPManagement.pdf](#)

2a1.33 **Level of Analysis** (Check the levels of analysis for which the measure is specified and tested): Clinician : Group/Practice, Clinician : Individual, Clinician : Team

2a1.34-35 **Care Setting** (Check all the settings for which the measure is specified and tested): Ambulatory Care : Clinician Office, Dialysis Facility, Home Health, Other:Domicillary, Rest Home or Custodial Care Services, Post Acute/Long Term Care Facility : Nursing Home/Skilled Nursing Facility

2a2. **Reliability Testing.** (Reliability testing was conducted with appropriate method, scope, and adequate demonstration of reliability.)

2a2.1 **Data/Sample** (Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):

- Four nephrology practice sites representing various types, locations and sizes were identified to participate in testing the measures
  - o The number of physicians per site ranged from 5-62 physicians
  - o The sites were located in four different regions: Midwestern, Western, Eastern, and Southern
  - o Patient visit volume ranged from 60-2,250 CKD patients and 240-2,800 ESRD patients seen per month
- Sample size per physician organization ranged from 24-30 (as shown below) for a total of 112 patients with Chronic Kidney Disease (CKD)
  - o Site 1: 24 CKD patients
  - o Site 2 : 29 CKD patients
  - o Site 3 : 29 CKD patients
  - o Site 4 : 30 CKD patients
- Sample selection: Data were collected from the medical records of the first 35 patients seen at each site after July 1, 2007.
- Data abstraction was completed for multiple patient visits per patient for a total of 674 patient visits.
- Data abstraction was performed in 2008

2a2.2 **Analytic Method** (Describe method of reliability testing & rationale):

Data abstracted from patient records were used to calculate inter-rater reliability for the measure.  
 Patients were randomly selected from visits for chronic kidney disease  
 Data analysis included:



- Percent agreement
- Kappa statistic to adjust for chance agreement

**2a2.3 Testing Results** (*Reliability statistics, assessment of adequacy in the context of norms for the test conducted*):  
This measure is highly reliable.

Blood Pressure Management Measure (N, % Agreement, Kappa ( 95% Confidence Interval))  
 Blood Pressure < 130/80 (323, 99.1 % Agreement, Kappa 0.00\* (-1.126 to 1.126))  
 Blood Pressure >= 130/80 with documented plan of care (251, 97.6 % Agreement, Kappa -0.0067\* (-0.0177 to 0.0043)  
 Blood Pressure >= 130/80 with documented plan of care (100, 100% Agreement, Kappa 1.00\*\*)

\*This is an example of the limitation of the Kappa statistic. While the agreement can be 90% or greater, if one classification category dominates in a 2X2 table, kappa can be significantly reduced. (<http://www.ajronline.org/cgi/content/full/184/5/1391>)

\*\* Kappa statistics cannot be calculated for 100% agreement but are given a value of 1.00 because of complete agreement. Confidence intervals cannot be calculated because to do so would involve dividing by zero which cannot be done.

**2b. VALIDITY. Validity, Testing, including all Threats to Validity:** H  M  L  I

**2b1.1 Describe how the measure specifications** (*measure focus, target population, and exclusions*) **are consistent with the evidence cited in support of the measure focus** (*criterion 1c*) **and identify any differences from the evidence:**

The evidence cited in support of the measure, demonstrates the association between patients with chronic kidney disease and hypertension. The guideline recommendations state that patients with CKD should be considered in the "highest risk" group for cardiovascular disease, and that the target blood pressure for CVD risk reduction in CKD should be <130/80 mmHg. The measure numerator captures the patient visits with blood pressure <130/80 mmHg OR > or = 130/80 mmHg with a documented plan of care. The plan of care should include one or more of the following: rechecking the blood pressure within 90 days, initiating or alternating pharmacologic therapy for blood pressure control, initiating or altering non-pharmacologic therapy through lifestyle changes for blood pressure control, and/or documenting a review of the patient's home blood pressure log which would indicate that the patient's blood pressure is or is not well controlled. Guideline recommendation statements that support the plan of care include: antihypertensive agents should be prescribed, lifestyle modifications recommended for CVD risk reduction should be recommended as part of the treatment regimen, and blood pressure can be determined by resting blood pressure measurement in the health-care provider's office (casual blood pressure [CBP]), self-measured blood pressure (SMBP), or ambulatory blood pressure monitoring (ABPM); patients should be taught to measure and record their blood pressure, whenever possible.

**2b2. Validity Testing.** (*Validity testing was conducted with appropriate method, scope, and adequate demonstration of validity.*)

**2b2.1 Data/Sample** (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

An expert panel was used to assess face validity of the measure. This panel consisted of 21 members, with representation from the following specialties: nephrology, pediatric nephrology, endocrinology, nursing, methodology, internal medicine, preventive medicine and family medicine.

Louis H. Diamond, MBChB, FCP (SA), FACP, FHIMSS (Work Group Co-Chair) (Nephrology, Methodology) President, Quality Healthcare Consultants, Rockville, MD

Barbara Fivush, MD (Work Group Co-Chair) (Nephrology - Pediatrics) Professor of Pediatrics, Division Chief of Pediatric Nephrology, Johns Hopkins University, Baltimore, MD

Paul M. Palevsky, MD, FACP, FCCD, FASN (Work Group Co-Chair) (Nephrology - Adult) Professor of Medicine, University of Pittsburgh School of Medicine, Chief, Renal Section, VA Pittsburgh Healthcare System, Pittsburgh, PA

Eileen D. Brewer, MD (Nephrology - Pediatrics) Professor and Head, Pediatric Renal Section, Baylor College of Medicine Chief, Renal Service, Texas Children's Hospital, Houston, TX

John W. Foreman, MD (Nephrology - Pediatrics) Department of Pediatrics, Professor of Pediatrics, Duke University, Durham, NC

Richard S. Goldman, MD (Nephrology - Adult, Methodology) Nephrology and Internal Medicine, Albuquerque, NM

Stuart L. Goldstein, MD (Nephrology - Pediatrics) Director, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center; Medical Director, Pheresis Service, Professor of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH

John Hartman, MD (Nephrology - Adult) CEO, Visonex, LLC, Treasurer, Wisconsin Medical Society, Green Bay, WI

## NOF #1633 Blood Pressure Management

Richard Hellman, MD, FACP, FACE (Endocrinology, Methodology) Clinical Professor of Medicine, University of Missouri-Kansas City School of Medicine, Private Practice, Diabetes & Endocrinology, North Kansas City, MO  
Jean L. Holley, MD, FACP (Nephrology - Adult) Clinical Professor of Medicine, University of Illinois, Urban-Champaign and Carle Physician Group, Urbana, IL  
Edward R. Jones, MD (Nephrology - Adult) Self-Employed, Delaware Valley Nephrology Associates, Philadelphia, PA  
Karen M. Kolbusz, RN, BSN, MBA, (Nursing, Joint Commission Liaison) Associate Project Director, The Joint Commission, Oakbrook Terrace, IL  
Craig B. Langman, MD (Nephrology - Pediatrics) The Isaac A. Abt MD Professor of Kidney Diseases and Head, Kidney Diseases, Feinberg School of Medicine, Northwestern University, and Children's Memorial Hospital, Chicago, IL  
Rajnish Mehrotra, MD (Nephrology - Adult) Professor of Medicine at David Geffen School of Medicine at UCLA and Associate Chief, Div of Nephrology and Hypertension, Harbor-UCLA Medical Center, Torrance, CA  
Alvin H. Moss, MD (Nephrology - Adult) Professor of Medicine, West Virginia University, Morgantown, WV  
Sharon A. Perlman, MD (Nephrology - Pediatrics) USF Pediatric Nephrology, All Children's Hospital, St. Petersburg, FL  
Paul D. Rockswold, MD, MPH (Preventive Medicine and Family Medicine) Physician Epidemiologist, Head of Health Analysis, Navy and Marine Corps Public Health Center, Suffolk, VA  
Candace C. Walworth, MD (Nephrology - Adult) Nephrology and Internal Medicine, Lewiston, ME  
Bradley Warady, MD (Nephrology - Pediatrics) Chief, Pediatric Nephrology, Children's Mercy Hospitals and Clinics, Kansas City, MO  
Steven J. Wassner, MD, FAAP (Nephrology - Pediatrics) Professor of Pediatrics, Vice-Chair for Education, Chief, Division of Nephrology & Hypertension, Hershey, PA  
Jerry Yee, MD (Nephrology - Adult) Division Head, Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI

**2b2.2 Analytic Method** (*Describe method of validity testing and rationale; if face validity, describe systematic assessment*):  
Face validity of the measure score as an indicator of quality was systematically assessed as follows.

After the measure was fully specified, the expert panel (Work Group membership) was asked to rate their agreement with the following statement:

Please rate your agreement with the following statement for each measure- the scores obtained from the measure as specified will accurately differentiate quality across providers.

Scale 1-5, where 1=Strongly Disagree; 3=Neither Disagree nor Agree; 5=Strongly Agree

**2b2.3 Testing Results** (*Statistical results, assessment of adequacy in the context of norms for the test conducted; if face validity, describe results of systematic assessment*):

The results of the expert panel rating of the validity statement were as follows:

N = 19; Mean rating = 4.37

Frequency Distribution of Ratings

1 - 0 (Strongly Disagree)

2 - 0

3 - 1 (Neither Disagree nor Agree)

4 - 10

5 - 8 (Strongly Agree)

**POTENTIAL THREATS TO VALIDITY.** (*All potential threats to validity were appropriately tested with adequate results.*)

**2b3. Measure Exclusions.** (*Exclusions were supported by the clinical evidence in 1c or appropriately tested with results demonstrating the need to specify them.*)

**2b3.1 Data/Sample for analysis of exclusions** (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

This measure does not have exclusions.

**2b3.2 Analytic Method** (*Describe type of analysis and rationale for examining exclusions, including exclusion related to patient preference*):

This measure does not have exclusions.

**2b3.3 Results** (*Provide statistical results for analysis of exclusions, e.g., frequency, variability, sensitivity analyses*):

This measure does not have exclusions.

**2b4. Risk Adjustment Strategy.** (*For outcome measures, adjustment for differences in case mix (severity) across measured entities was appropriately tested with adequate results.*)

**2b4.1 Data/Sample** (*Description of the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

This measure is not risk adjusted.

**2b4.2 Analytic Method** (*Describe methods and rationale for development and testing of risk model or risk stratification including selection of factors/variables*):

This measure is not risk adjusted.

**2b4.3 Testing Results** (*Statistical risk model: Provide quantitative assessment of relative contribution of model risk factors; risk model performance metrics including cross-validation discrimination and calibration statistics, calibration curve and risk decile plot, and assessment of adequacy in the context of norms for risk models. Risk stratification: Provide quantitative assessment of relationship of risk factors to the outcome and differences in outcomes among the strata*):

This measure is not risk adjusted.

**2b4.4 If outcome or resource use measure is not risk adjusted, provide rationale and analyses to justify lack of adjustment:** This measure looks at an intermediate outcome but also includes a process component. Patients who do not meet the outcome but have a plan of care can still meet the measure; therefore, the measure does not need to be risk adjusted.

**2b5. Identification of Meaningful Differences in Performance.** (*The performance measure scores were appropriately analyzed and discriminated meaningful differences in quality.*)

**2b5.1 Data/Sample** (*Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included*):

PCPI Testing Project:

- Four nephrology practice sites representing various types, locations and sizes were identified to participate in testing the measures
  - o The number of physicians per site ranged from 5-62 physicians
  - o The sites were located four different regions: Midwestern, Western, Eastern, and Southern
  - o Patient visit volume ranged from 60-2,250 CKD patients and 240-2,800 ESRD patients seen per month
- Sample size per practice site ranged from 24-30 (as shown below) for a total of 112 patients with Chronic Kidney Disease (CKD)
  - o Site 1: 24 CKD patients
  - o Site 2 : 29 CKD patients
  - o Site 3 : 29 CKD patients
  - o Site 4 : 30 CKD patients
- Sample selection: Data were collected from the first 35 patients seen at the site after July 1, 2007.
- Data abstraction was completed for multiple patient visits per patient for a total of 674 patient visits.
- Data abstraction performed in 2008.

CMS Physician Quality Reporting Initiative:

45,814 patients were reported on for the 2008 program, the most recent year for which data are available.

The following information is for the 2009 program, the only year for which such data are available.

Clinical Condition and Measure: #122 Blood Pressure Management

# Eligible Professionals: 45,994

# Professionals Reporting >=1 Valid QDC: 721

NOF #1633 Blood Pressure Management

% Professionals Reporting >=1 Valid QDC: 1.57%  
# Professionals Satisfactorily Reporting: 298  
% Professionals Satisfactorily Reporting: 41.33%

**2b5.2 Analytic Method** *(Describe methods and rationale to identify statistically significant and practically/meaningfully differences in performance):*

The inter-quartile range (IQR) was calculated, which provides a measure of the dispersion of performance.

**2b5.3 Results** *(Provide measure performance results/scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance):*

PCPI Testing Project Results:

Scores on this measure: N = 674 Mean = 85 %, Range (76% - 95%)

CMS Physician Quality Reporting Initiative:

This measure was used in the CMS Physician Quality Reporting Initiative, in the claims option (2008, 2009, 2010) as well as the Registry and Measure Group options (2009, 2010). The measure is also being used in the CMS Physician Quality Reporting System for 2011.

43.2 % of patients reported on did not receive the optimal care. There is significant variation in performance on this measure in the PQRI program as shown by the 2008 data, the most recent available(1).

10th percentile: 6.67 %

25th percentile: 25.76 %

50th percentile: 67.53 %

75th percentile: 92.54 %

90th percentile: 100 %

The inter-quartile range (IQR) provides a measure of the dispersion of performance. The IQR is 66.8, and indicates that 50% of physicians have performance on this measure ranging from 25.76% and 92.54%. A quarter of reporting physicians have performance on this measure which is greater than 92.54%, while a quarter have performance on this measure less than 25.76%.

1. Confidential CMS PQRI 2008 Performance Information by Measure. Jan-Sept TAP file.

**2b6. Comparability of Multiple Data Sources/Methods.** *(If specified for more than one data source, the various approaches result in comparable scores.)*

**2b6.1 Data/Sample** *(Describe the data or sample including number of measured entities; number of patients; dates of data; if a sample, characteristics of the entities included):*

This measure has not been compared across data sources.

**2b6.2 Analytic Method** *(Describe methods and rationale for testing comparability of scores produced by the different data sources specified in the measure):*

This measure has not been compared across data sources.

**2b6.3 Testing Results** *(Provide statistical results, e.g., correlation statistics, comparison of rankings; assessment of adequacy in the context of norms for the test conducted):*

This measure has not been compared across data sources.

**2c. Disparities in Care:** H  M  L  I  NA  *(If applicable, the measure specifications allow identification of disparities.)*

**2c.1 If measure is stratified for disparities, provide stratified results** *(Scores by stratified categories/cohorts):* We encourage the results of this measure to be stratified by race, ethnicity, primary language, and gender, and have included these variables as recommended data elements to be collected.

**2c.2 If disparities have been reported/identified (e.g., in 1b), but measure is not specified to detect disparities, please explain:**

The PCPI advocates that performance measure data should, where possible, be stratified by race, ethnicity, and primary language

to assess disparities and initiate subsequent quality improvement activities addressing identified disparities, consistent with recent national efforts to standardize the collection of race and ethnicity data. A 2008 NQF report endorsed 45 practices including stratification by the aforementioned variables.(1) A 2009 IOM report “recommends collection of the existing Office of Management and Budget (OMB) race and Hispanic ethnicity categories as well as more fine-grained categories of ethnicity(referred to as granular ethnicity and based on one’s ancestry) and language need (a rating of spoken English language proficiency of less than very well and one’s preferred language for health-related encounters).”(2)

References:

(1)National Quality Forum Issue Brief (No.10). Closing the Disparities Gap in Healthcare Quality with Performance Measurement and Public Reporting. Washington, DC: NQF, August 2008.

(2)Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement. March 2010. AHRQ Publication No. 10-0058-EF. Agency for Healthcare Research and Quality, Rockville, MD. Available at: <http://www.ahrq.gov/research/iomracereport>. Accessed May 25, 2010.

2.1-2.3 Supplemental Testing Methodology Information:

Steering Committee: Overall, was the criterion, *Scientific Acceptability of Measure Properties*, met? (Reliability and Validity must be rated moderate or high) Yes  No   
Provide rationale based on specific subcriteria:

If the Committee votes No, STOP

3. USABILITY

Extent to which intended audiences (e.g., consumers, purchasers, providers, policy makers) can understand the results of the measure and are likely to find them useful for decision making. (evaluation criteria)

C.1 Intended Purpose/ Use (Check all the purposes and/or uses for which the measure is intended): Professional Certification or Recognition Program, Public Reporting, Quality Improvement (Internal to the specific organization)

3.1 Current Use (Check all that apply; for any that are checked, provide the specific program information in the following questions): Public Reporting, Professional Certification or Recognition Program, Quality Improvement (Internal to the specific organization)

3a. Usefulness for Public Reporting: H  M  L  I   
(The measure is meaningful, understandable and useful for public reporting.)

3a.1. Use in Public Reporting - disclosure of performance results to the public at large (If used in a public reporting program, provide name of program(s), locations, Web page URL(s)). If not publicly reported in a national or community program, state the reason AND plans to achieve public reporting, potential reporting programs or commitments, and timeline, e.g., within 3 years of endorsement: [For Maintenance – If not publicly reported, describe progress made toward achieving disclosure of performance results to the public at large and expected date for public reporting; provide rationale why continued endorsement should be considered.]

This measure is currently being used in the CMS Physician Quality Reporting System for 2011, and will provide information about clinician participation to the public. This measure was also used in the 2010 CMS PQRS program for 2010.

The results from the 2010 PQRS program can be found on the CMS website: <http://www.cms.gov/PQRS/>

This measure has been used in the CMS Physician Quality Reporting Initiative since 2008.

3a.2. Provide a rationale for why the measure performance results are meaningful, understandable, and useful for public reporting. If usefulness was demonstrated (e.g., focus group, cognitive testing), describe the data, method, and results: The PCPI,

NQF #1633 Blood Pressure Management

RPA and ASPN believe that the reporting of participation information is a beneficial first step on a trajectory toward the public reporting of performance results, which is appropriate since the measure has been tested and the reliability of the performance data has been validated. NQF endorsement will facilitate our ongoing progress toward this public reporting objective.

**3.2 Use for other Accountability Functions (payment, certification, accreditation).** If used in a public accountability program, provide name of program(s), locations, Web page URL(s): [This measure may be used in a Maintenance of Certification program.](#)

**3b. Usefulness for Quality Improvement:** H  M  L  I

*(The measure is meaningful, understandable and useful for quality improvement.)*

**3b.1. Use in QI.** If used in quality improvement program, provide name of program(s), locations, Web page URL(s):

**[For Maintenance – If not used for QI, indicate the reasons and describe progress toward using performance results for improvement].**

All PCPI measures are suitable for use in quality improvement initiatives and are made freely available on the PCPI website and through the implementation efforts of medical specialty societies and other PCPI members. The PCPI strongly encourages the use of its measures in QI initiatives and seeks to provide information on such initiatives to PCPI members.

**3b.2. Provide rationale for why the measure performance results are meaningful, understandable, and useful for quality improvement.** If usefulness was demonstrated (e.g., QI initiative), describe the data, method and results:

The PCPI, RPA and ASPN believe that the use of PCPI measures in quality improvement initiatives is a beneficial way to gather scientific data with which to improve physician performance. This is appropriate since the measure has been tested and the reliability of the performance data has been validated. NQF endorsement will facilitate our ongoing progress toward this quality improvement objective.

**Overall, to what extent was the criterion, *Usability*, met?** H  M  L  I

Provide rationale based on specific subcriteria:

#### 4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

**4a. Data Generated as a Byproduct of Care Processes:** H  M  L  I

**4a.1-2 How are the data elements needed to compute measure scores generated?** (Check all that apply).

Data used in the measure are:

[generated by and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition](#)

**4b. Electronic Sources:** H  M  L  I

**4b.1 Are the data elements needed for the measure as specified available electronically** (Elements that are needed to compute measure scores are in defined, computer-readable fields): [ALL data elements in electronic health records \(EHRs\)](#)

**4b.2 If ALL data elements are not from electronic sources, specify a credible, near-term path to electronic capture, OR provide a rationale for using other than electronic sources:**

**4c. Susceptibility to Inaccuracies, Errors, or Unintended Consequences:** H  M  L  I

**4c.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measurement identified during testing and/or operational use and strategies to prevent, minimize, or detect. If audited, provide results:**

[We are not aware of any unintended consequences related to this measurement.](#)

**4d. Data Collection Strategy/Implementation:** H  M  L  I

**A.2 Please check if either of the following apply** (regarding proprietary measures):

**4d.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data, missing data, timing and frequency of data collection, sampling, patient confidentiality, time and cost of data collection, other feasibility/implementation issues** (e.g., fees for use of proprietary measures):

NQF #1633 Blood Pressure Management

During testing, documentation of proteinuria/albuminuria showed that patient's proteinuria status could fluctuate due to positive and negative microalbumin tests throughout the year. The measure is specified at the visit level and indicates that the patient must have albuminuria associated with that visit in order to qualify for the measure, which sufficiently clarifies the measure specifications.

Overall, to what extent was the criterion, *Feasibility*, met? H  M  L  I

Provide rationale based on specific subcriteria:

**OVERALL SUITABILITY FOR ENDORSEMENT**

Does the measure meet all the NQF criteria for endorsement? Yes  No

Rationale:

**If the Committee votes No, STOP.**

**If the Committee votes Yes, the final recommendation is contingent on comparison to related and competing measures.**

**5. COMPARISON TO RELATED AND COMPETING MEASURES**

If a measure meets the above criteria and there are endorsed or new related measures (either the same measure focus or the same target population) or competing measures (both the same measure focus and the same target population), the measures are compared to address harmonization and/or selection of the best measure before a final recommendation is made.

5.1 If there are related measures (*either same measure focus or target population*) or competing measures (*both the same measure focus and same target population*), list the NQF # and title of all related and/or competing measures:

0013 : Hypertension: Blood Pressure Control

**5a. Harmonization**

5a.1 If this measure has EITHER the same measure focus OR the same target population as [NQF-endorsed measure\(s\)](#): Are the measure specifications completely harmonized?

5a.2 If the measure specifications are not completely harmonized, identify the differences, rationale, and impact on interpretability and data collection burden:

**5b. Competing Measure(s)**

5b.1 If this measure has both the same measure focus and the same target population as NQF-endorsed measure(s): Describe why this measure is superior to competing measures (*e.g., a more valid or efficient way to measure quality*); OR provide a rationale for the additive value of endorsing an additional measure. (*Provide analyses when possible*):  
We are not aware of any competing measures for the CKD population.

**CONTACT INFORMATION**

Co.1 Measure Steward (Intellectual Property Owner): [American Medical Association, 515 N State St, Chicago, Illinois, 60654](#)

Co.2 Point of Contact: [Mark, Antman, DDS, MBA, mark.antman@ama-assn.org, 312-464-5056-](#)

Co.3 Measure Developer if different from Measure Steward: [American Medical Association, 515 N State St, Chicago, Illinois, 60654](#)

Co.4 Point of Contact: [Katherine, Ast, MSW, LCSW, katherine.ast@ama-assn.org, 312-464-4920-](#)

Co.5 Submitter: [Diedra, Joseph, MPH, diedra.joseph@ama-assn.org, 312-464-4904-](#), American Medical Association

Co.6 Additional organizations that sponsored/participated in measure development:  
[Renal Physicians Association, American Society of Pediatric Nephrology](#)

Co.7 Public Contact: [Mark, Antman, DDS, MBA, mark.antman@ama-assn.org, 312-464-5056-](#), American Medical Association

**ADDITIONAL INFORMATION**

**Workgroup/Expert Panel involved in measure development**

**Ad.1 Provide a list of sponsoring organizations and workgroup/panel members' names and organizations. Describe the members' role in measure development.**

- Louis H. Diamond, MBChB, FCP (SA), FACP, FHIMSS (Work Group Co-Chair) (Nephrology, Methodology) President, Quality Healthcare Consultants, Rockville, MD
- Barbara Fivush, MD (Work Group Co-Chair) (Nephrology - Pediatrics) Professor of Pediatrics, Division Chief of Pediatric Nephrology, Johns Hopkins University, Baltimore, MD
- Paul M. Palevsky, MD, FACP, FCCD, FASN (Work Group Co-Chair) (Nephrology - Adult) Professor of Medicine, University of Pittsburgh School of Medicine, Chief, Renal Section, VA Pittsburgh Healthcare System, Pittsburgh, PA
- Eileen D. Brewer, MD (Nephrology - Pediatrics) Professor and Head, Pediatric Renal Section, Baylor College of Medicine Chief, Renal Service, Texas Children's Hospital, Houston, TX
- John W. Foreman, MD (Nephrology - Pediatrics) Department of Pediatrics, Professor of Pediatrics, Duke University, Durham, NC
- Richard S. Goldman, MD (Nephrology - Adult, Methodology) Nephrology and Internal Medicine, Albuquerque, NM
- Stuart L. Goldstein, MD (Nephrology - Pediatrics) Director, Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center; Medical Director, Pheresis Service, Professor of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
- John Hartman, MD (Nephrology - Adult) CEO, Visonex, LLC, Treasurer, Wisconsin Medical Society, Green Bay, WI
- Richard Hellman, MD, FACP, FACE (Endocrinology, Methodology) Clinical Professor of Medicine, University of Missouri-Kansas City School of Medicine, Private Practice, Diabetes & Endocrinology, North Kansas City, MO
- Jean L. Holley, MD, FACP (Nephrology - Adult) Clinical Professor of Medicine, University of Illinois, Urban-Champaign and Carle Physician Group, Urbana, IL
- Edward R. Jones, MD (Nephrology - Adult) Self-Employed, Delaware Valley Nephrology Associates, Philadelphia, PA
- Karen M. Kolbusz, RN, BSN, MBA, (Nursing, Joint Commission Liaison) Associate Project Director, The Joint Commission, Oakbrook Terrace, IL
- Craig B. Langman, MD (Nephrology - Pediatrics) The Isaac A. Abt MD Professor of Kidney Diseases and Head, Kidney Diseases, Feinberg School of Medicine, Northwestern University, and Children's Memorial Hospital, Chicago, IL
- Rajnish Mehrotra, MD (Nephrology - Adult) Professor of Medicine at David Geffen School of Medicine at UCLA and Associate Chief, Div of Nephrology and Hypertension, Harbor-UCLA Medical Center, Torrance, CA
- Alvin H. Moss, MD (Nephrology - Adult) Professor of Medicine, West Virginia University, Morgantown, WV
- Sharon A. Perlman, MD (Nephrology - Pediatrics) USF Pediatric Nephrology, All Children's Hospital, St. Petersburg, FL
- Paul D. Rockswold, MD, MPH (Preventive Medicine and Family Medicine) Physician Epidemiologist, Head of Health Analysis, Navy and Marine Corps Public Health Center, Suffolk, VA
- Candace C. Walworth, MD (Nephrology - Adult) Nephrology and Internal Medicine, Lewiston, ME
- Bradley Warady, MD (Nephrology - Pediatrics) Chief, Pediatric Nephrology, Children's Mercy Hospitals and Clinics, Kansas City, MO
- Steven J. Wassner, MD, FAAP (Nephrology - Pediatrics) Professor of Pediatrics, Vice-Chair for Education, Chief, Division of Nephrology & Hypertension, Hershey, PA
- Jerry Yee, MD (Nephrology - Adult) Division Head, Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI

PCPI measures are developed through cross-specialty, multi-disciplinary work groups. All medical specialties and other health care professional disciplines participating in patient care for the clinical condition or topic under study are invited to participate as equal contributors to the measure development process. In addition, the PCPI strives to include on its work groups individuals representing the perspectives of patients, consumers, private health plans, and employers. This broad-based approach to measure development ensures buy-in on the measures from all stakeholders and minimizes bias toward any individual specialty or stakeholder group. All work groups have at least two co-chairs who have relevant clinical and/or measure development expertise and who are responsible for ensuring that consensus is achieved and that all perspectives are voiced.

**Ad.2 If adapted, provide title of original measure, NQF # if endorsed, and measure steward. Briefly describe the reasons for adapting the original measure and any work with the original measure steward:** This is a new measure submission.

**Measure Developer/Steward Updates and Ongoing Maintenance**

**Ad.3 Year the measure was first released:** 2007



Ad.4 Month and Year of most recent revision: 06, 2011

Ad.5 What is your frequency for review/update of this measure? Every 3 years or as new evidence becomes available that materially affects the measures.

Ad.6 When is the next scheduled review/update for this measure?

Ad.7 Copyright statement: Physician Performance Measures (Measures) and related data specifications have been developed by the American Medical Association (AMA) convened Physician Consortium for Performance Improvement® (PCPI™).

These performance Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications.

The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA (on behalf of the PCPI). Neither the AMA, PCPI nor its members shall be responsible for any use of the Measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

© 2010 American Medical Association. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004- 2010 American Medical Association. LOINC® copyright 2004-2010 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms® (SNOMED CT®) copyright 2004-2010 International Health Terminology Standards Development Organisation. All Rights Reserved.

Ad.8 Disclaimers:

Ad.9 Additional Information/Comments: The next scheduled review/update for this measure will be in 2014.

The following updates were made on 11/08/11:

Specifications

De.2 The measure description was updated and "proteinuria" replaced "albuminuria."

2a1.4 The denominator language was updated, as indicated above. The definition of proteinuria was also updated.

Importance:

1c.4 The directness of evidence to the specified measure was updated as indicated above.

Date of Submission (MM/DD/YY): 06/08/2011

## PCPI eSpecification

<b>Clinical Topic</b>	<b>Adult Kidney Disease</b>
<b>Measure Title</b>	<b>Blood Pressure Management</b>
<b>Measure #</b>	<b>AKID-1</b>
<b>Measure Description</b>	Percentage of patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4, or 5 not receiving RRT) and albuminuria with a blood pressure <130/80 mm/Hg or ≥130/80 mmHg with a documented plan of care
<b>Measurement Period</b>	12 consecutive months
<b>Initial Patient Population</b>	<p>Patient Age: Patients aged 18 years and older starts before the start of the measurement period</p> <p>Diagnosis Active: Patient has a diagnosis of CKD and albuminuria starts before or during encounter during measurement period</p> <p>Encounter: At least two visits with the physician, physician’s assistant, or nurse practitioner during the measurement period</p>
<b>Denominator Statement</b>	<p>All patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4, or 5, not receiving RRT) and albuminuria</p> <p>Definition of albuminuria: &gt;300mg of albumin in the urine per 24 hours</p> <p>Definition of RRT (Renal Replacement Therapy): For the purposes of this measure, RRT (Renal Replacement Therapy) includes hemodialysis, peritoneal dialysis, and kidney transplantation</p>
<b>Numerator Statement</b>	<p>Patient visits with blood pressure &lt; 130/80 mm/Hg or ≥130/80 mmHg with a documented plan of care*</p> <p>Plan of Care: *A documented plan of care should include one or more of the following: recheck blood pressure within 90 days; initiate or alter pharmacologic therapy for blood pressure control; initiate or alter non-pharmacologic therapy (lifestyle changes) for blood pressure control; documented review of patient’s home blood pressure log which indicates that patient’s blood pressure is or is not well controlled</p> <p>Note: report the following for this measure:            % of patient visits meeting blood pressure &lt; 130/80 mmHg (component 1)            % of patient visits meeting blood pressure ≥ 130/80 mmHg with plan of care (component 2)            % of patient visits meeting blood pressure &lt; 130/80 mmHg AND patient visits meeting blood pressure ≥ 130/80 mmHg with plan of care (total measure score)</p>
<b>Denominator Exceptions</b>	None

**Adult Kidney Disease  
DRAFT Data Elements for PCPI eSpecification**

**Measure #1 : Blood Pressure Management**

QDM* Standard Category	QDM* Data Type	Standard Terminology	Constraints	Value Set Name	Value of Data Element	Data Source	Comments/Rationale
Measure Timing	N/A	N/A	TBD by measure implementer	Measurement Start Date			
Measure Timing	N/A	N/A	TBD by measure implementer	Measurement End Date			
Individual Characteristic	Patient Characteristic	TBD	during measurement period	Gender		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	TBD	during measurement period	Race		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	TBD	during measurement period	Ethnicity		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	TBD	during measurement period	Primary Language		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	This data element is collected for the purpose of stratifying results in an effort to highlight disparities.
Individual Characteristic	Patient Characteristic	LN	starts before the start of measurement period	Date of Birth		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	
Individual Characteristic	Patient Characteristic	Calculated	starts before the start of measurement period	Age	≥ 18	<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	Measurement start date minus Date of Birth must be greater than or equal to 18 years.
Condition / Diagnosis / Problem	Diagnosis, Active	I9, I10, SNM	starts before or during encounter during measurement period	Chronic Kidney Disease, Stage III		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	
Condition / Diagnosis / Problem	Diagnosis, Active	I9, I10, SNM	starts before or during encounter during measurement period	Chronic Kidney Disease, Stage IV		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	
Condition / Diagnosis / Problem	Diagnosis, Active	I9, I10, SNM	starts before or during encounter during measurement period	Chronic Kidney Disease, Stage V		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	
Encounter	Encounter, Performed	CPT	during measurement period	Encounter, Outpatient	count ≥ 2	<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	
Symptom	Symptom, Active	I9, I10, SNM	starts before or during encounter during measurement period	albuminuria		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	
Laboratory Test	Laboratory Test, Performed	LN	starts before or during encounter during measurement period	albumin		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	
Laboratory Test	Laboratory Test, Result	LN	starts before or during encounter during measurement period	albumin	> 300mg/24hrs	<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	
Physical Exam	Physical Exam, Finding	CPT II, SNM	during encounter	Blood Pressure, Systolic	< 130	<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	Systolic, < 130
					≥ 130	<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	Systolic, ≥ 130
Physical Exam	Physical Exam, Finding	CPT II, SNM	during encounter	Blood Pressure, Diastolic	< 80	<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	Diastolic, < 80
					≥ 80	<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> <li>Electronic Health Record (EHR)</li> </ul>	Diastolic, ≥ 80
Care Plan	Care Plan, Documented	CPT II	during encounter	Plan of Care		<ul style="list-style-type: none"> <li>Electronic Administrative Claims</li> </ul>	This value set will encompass: Blood Pressure Recheck in 90 days Start or change pharmacologic therapy Start or change non-pharmacologic therapy Review of patient's home blood pressure log
Physical Exam	Physical Exam, Order	SNM	during encounter	Blood Pressure, Plan to Recheck within 90 days		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	
Medication	Medication, Active	RxNorm	during encounter	Anti-Hypertensive		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	This value set will include both single agent anti-hypertensives and multi agent anti-hypertensives to cover the 'Start or change pharmacologic therapy' portion of the Plan of Care.
Medication	Medication, Order	RxNorm	during encounter	Anti-Hypertensive		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	This value set will include both single agent anti-hypertensives and multi agent anti-hypertensives to cover the 'Start or change pharmacologic therapy' portion of the Plan of Care.
Intervention	Intervention, Order	SNM	during encounter	Anti-Hypertensive Non-pharmacologic Therapy		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	To include lifestyle changes (eg, diet, exercise, nutrition)
Intervention	Intervention, Performed	SNM	during encounter	Review of Home Blood Pressure Log		<ul style="list-style-type: none"> <li>Electronic Health Record (EHR)</li> </ul>	
No Valid Exceptions							

\*The Quality Data Model (QDM), Version 2.1, was developed by National Quality Forum (NQF).

# PCPI eSpecification

## Measure Logic for Adult Kidney Disease : Blood Pressure Management

**Measure Description:** Percentage of patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4, or 5, not receiving RRT) and albuminuria with a blood pressure < 130/80 mmHg OR ≥ 130/80 mmHg with a documented plan of care

**Measurement Period:** 12 Consecutive Months

**PCPI Measure #:** AKID-1

Identify Patients in Initial Patient Population (IPP)	Identify Patients in Denominator (D)	Identify Patients in Numerator (N)	Identify Patients who have valid Denominator Exceptions * (E)
<p style="text-align: center;">P A T I E N T A G E <sup>1</sup> 18 and older</p> <p style="text-align: center;">And</p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="border: 1px solid black; padding: 5px; width: 30%;"> <p style="text-align: center;">DIAGNOSIS Active <sup>2</sup> Chronic Kidney Disease, Stage III Value Set 000284</p> </div> <div style="text-align: center;">OR</div> <div style="border: 1px solid black; padding: 5px; width: 30%;"> <p style="text-align: center;">DIAGNOSIS Active <sup>3</sup> Chronic Kidney Disease, Stage IV Value Set 000285</p> </div> <div style="text-align: center;">OR</div> <div style="border: 1px solid black; padding: 5px; width: 30%;"> <p style="text-align: center;">DIAGNOSIS Active <sup>4</sup> Chronic Kidney Disease, Stage V Value Set 000286</p> </div> </div> <p style="text-align: center;">And</p> <div style="border: 1px solid black; padding: 5px; width: 30%; margin: 0 auto;"> <p style="text-align: center;">ENCOUNTER <sup>5</sup> Outpatient Value Set 000002</p> </div>	<p style="border: 1px solid black; padding: 5px; width: 80%; margin: 0 auto;">See PAGE 2 for Denominator Inclusion</p>	<p style="border: 1px solid black; padding: 5px; width: 80%; margin: 0 auto;">See PAGE 2 for Numerator Inclusions</p>	<p style="border: 1px solid black; padding: 5px; width: 80%; margin: 0 auto;">See PAGE 2 for Denominator Exceptions</p>

PARAMETER SPECIFICATIONS (Value Sets are found in the Coding Appendices):

IPP: <sup>1</sup> Patient Age: measurement start date minus birth date (value set 000307) ≥ 18 years starts before the start of measurement period; <sup>2,3,4</sup> Diagnosis, Active: starts before or during encounter during measurement period;

<sup>5</sup> Encounter: count ≥ 2 during measurement period;


# PCPI eSpecification

## Measure Logic for Adult Kidney Disease : Blood Pressure Management

**Measure Description:** Percentage of patient visits for those patients aged 18 years and older with a diagnosis of CKD (stage 3, 4, or 5, not receiving RRT) and albuminuria with a blood pressure < 130/80 mmHg OR ≥ 130/80 mmHg with a documented plan of care

**Measurement Period:** 12 Consecutive Months

**PCPI Measure #:** AKID-1



PARAMETER SPECIFICATIONS (Value Sets are found in the Coding Appendices):

D: <sup>6</sup> Symptom, Active: starts before or during encounter during measurement period, qualitative; <sup>7</sup> Laboratory Test, Performed: starts before or during encounter during measurement period; <sup>8</sup> Laboratory Test, Result: starts before or during encounter during measurement period, quantitative, > 300mg/24 hours;

N: <sup>9</sup> Physical Exam, Finding: during encounter, Systolic < 130 mmHg; <sup>10</sup> Physical Exam, Finding: during encounter, Diastolic < 80 mmHg; <sup>11</sup> Physical Exam, Finding: during encounter, Systolic, ≥ 130 mmHg; <sup>12</sup> Physical Exam, Finding: Diastolic, ≥ 80 mmHg; <sup>9 10 11 12</sup> Physical Exam, Finding: if multiple BP measurements taken at a single encounter, use the most recent measurement during that encounter; <sup>13</sup> Care Plan: during encounter; <sup>14</sup> Medication, Prescribed: active or ordered during measurement period;

For this measure, report number of patients for each numerator component separately AND number of patients for total numerator.

\*Coded examples are NOT intended to be an exhaustive list. Exceptions will vary for each patient and situation.

© 2011 American Medical Association. All Rights Reserved.

**Basic Measure Calculation:**

$$\frac{(N)}{(D) - (E)} = \%$$

The PCPI strongly recommends that exception rates also be computed and reported alongside performance rates as follows:

**Exception Calculation:**

$$\frac{(E)}{(D)} = \%$$

**Exception Types:**

E= E1 (Medical Exceptions) + E2 (Patient Exceptions) + E3 (System Exceptions)

**For patients who have more than one valid exception, only one exception should be counted when calculating the exception rate**

<p><b>Initial Patient Population (IPP)</b></p> <p><b>Definition:</b> The initial patient population identifies the general group of patients that the performance measure is designed to address; usually focused on a specific clinical condition (e.g., coronary artery disease, asthma). For example, a patient aged 18 years and older with a diagnosis of CAD who has at least 2 visits during the measurement period.</p>	<p><b>Denominator (D)</b></p> <p><b>Definition:</b> The denominator defines the specific group of patients for inclusion in a specific performance measure based on specific criteria (e.g., patient's age, diagnosis, prior MI). In some cases, the denominator may be identical to the initial patient population.</p>	<p><b>Numerator (N)</b></p> <p><b>Definition:</b> The numerator defines the group of patients in the denominator for whom a process or outcome of care occurs (e.g., flu vaccine received).</p>	<p><b>Denominator Exceptions (E)</b></p> <p><b>Definition:</b> Denominator exceptions are the valid reasons why patients who are included in the denominator population did not receive a process or outcome of care (described in the numerator). Patients may have Denominator Exceptions for medical reasons (e.g., patient has an egg allergy so they did not receive flu vaccine); patient reasons (e.g., patient declined flu vaccine); or system reasons (e.g., patient did not receive flu vaccine due to vaccine shortage). These cases are removed from the denominator population for the performance calculation, however the number of patients with valid exceptions should be calculated and reported. This group of patients constitutes the Denominator Exception reporting population – patients for whom the numerator was not achieved and there is a valid Denominator Exception.</p>
<p>Find the patients who meet the Initial Patient Population criteria (IPP)</p>	<p>Find the patients who qualify for the denominator (D):</p> <ul style="list-style-type: none"> <li>○ From the patients within the Patient Population criteria (IPP) select those people who meet Denominator selection criteria.</li> </ul> <p>(In some cases the IPP and D are identical).</p>	<p>Find the patients who qualify for the Numerator (N):</p> <ul style="list-style-type: none"> <li>○ From the patients within the Denominator (D) criteria, select those people who meet Numerator selection criteria.</li> <li>○ Validate that the number of patients in the numerator is less than or equal to the number of patients in the denominator</li> </ul>	<p>From the patients who did not meet the Numerator criteria, determine if the patient meets any criteria for the Denominator Exception (E1 + E2+E3). If they meet any criteria, they should be removed from the Denominator for performance calculation. As a point of reference, these cases are removed from the denominator population for the performance calculation, however the number of patients with valid exceptions should be calculated and reported.</p>

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000307	AKID	1	IPP	Birth Date	Individual Characteristic	LN	21112-8	Birth date: TmStp:Pt:Patient:Qn:
000284	AKID	1	IPP	Chronic Kidney Disease, Stage III	Condition / Diagnosis / Problem	I9	585.3	Chronic Kidney Disease, Stage III (Moderate)
000284	AKID	1	IPP	Chronic Kidney Disease, Stage III	Condition / Diagnosis / Problem	I10	N18.3	Chronic Kidney Disease, Stage III (moderate)
000284	AKID	1	IPP	Chronic Kidney Disease, Stage III	Condition / Diagnosis / Problem	SNM	433144002	Chronic kidney disease stage 3 (disorder)
000285	AKID	1	IPP	Chronic Kidney Disease, Stage IV	Condition / Diagnosis / Problem	I9	585.4	Chronic Kidney Disease, Stage IV (Severe)
000285	AKID	1	IPP	Chronic Kidney Disease, Stage IV	Condition / Diagnosis / Problem	I10	N18.4	Chronic Kidney Disease, Stage IV (severe)
000285	AKID	1	IPP	Chronic Kidney Disease, Stage IV	Condition / Diagnosis / Problem	SNM	431857002	Chronic kidney disease stage 4 (disorder)
000286	AKID	1	IPP	Chronic Kidney Disease, Stage V	Condition / Diagnosis / Problem	I9	585.5	Chronic Kidney Disease, Stage V
000286	AKID	1	IPP	Chronic Kidney Disease, Stage V	Condition / Diagnosis / Problem	I10	N18.5	Chronic Kidney Disease, Stage V
000286	AKID	1	IPP	Chronic Kidney Disease, Stage V	Condition / Diagnosis / Problem	SNM	433146000	Chronic kidney disease stage 5 (disorder)
000002	AKID	1	IPP	Encounter	Encounter	CPT	99201	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99202	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99203	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99204	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99205	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99211	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99212	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99213	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99214	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99215	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99241	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99242	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99243	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99244	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99245	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99304	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99305	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99306	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99307	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99308	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99309	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99310	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99324	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99325	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99326	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99327	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99328	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99334	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99335	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99336	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99337	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99341	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99342	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99343	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99344	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99345	

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000002	AKID	1	IPP	Encounter	Encounter	CPT	99347	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99348	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99349	
000002	AKID	1	IPP	Encounter	Encounter	CPT	99350	
000292	AKID	1	D	Albumin	Laboratory Test	LN	30003-8	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	30165-5	Phosphatidylcholine/Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	3037-9	Prealbumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	30562-3	Surfactant/Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	32293-3	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	32294-1	Albumin/Creatinine
000292	AKID	1	D	Albumin	Laboratory Test	LN	33467-2	Prealbumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	34535-5	Microalbumin/Creatinine ratio panel
000292	AKID	1	D	Albumin	Laboratory Test	LN	35191-6	Bilirubin.glucuronidated+Bilirubin.albumin bound
000292	AKID	1	D	Albumin	Laboratory Test	LN	35672-5	Bilirubin.glucuronidated+Bilirubin.albumin bound/Bilirubin.total
000292	AKID	1	D	Albumin	Laboratory Test	LN	35706-1	Albumin/Protein.total
000292	AKID	1	D	Albumin	Laboratory Test	LN	40046-5	Albumin <pre>XXX challenge</pre>
000292	AKID	1	D	Albumin	Laboratory Test	LN	40047-3	Albumin^45M pre XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40048-1	Albumin^30M post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40049-9	Albumin^45M post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40050-7	Albumin^1H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40051-5	Albumin^1.5H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40052-3	Albumin^2H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40053-1	Albumin^3H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40054-9	Albumin^4H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40055-6	Albumin^5H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40056-4	Albumin^6H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40057-2	Albumin^6.5H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40058-0	Albumin^8H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40059-8	Albumin^12H post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40060-6	Albumin^1D post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40061-4	Albumin^2D post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40062-2	Albumin^3D post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40063-0	Albumin^4D post XXX challenge
000292	AKID	1	D	Albumin	Laboratory Test	LN	40599-3	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	40857-5	Prealbumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	43212-0	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	43605-5	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	43606-3	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	43607-1	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	44707-8	Albumin/Creatinine
000292	AKID	1	D	Albumin	Laboratory Test	LN	44292-1	Albumin/Creatinine
000292	AKID	1	D	Albumin	Laboratory Test	LN	44293-9	Albumin/Globulin
000292	AKID	1	D	Albumin	Laboratory Test	LN	44294-7	Albumin/Globulin
000292	AKID	1	D	Albumin	Laboratory Test	LN	44429-9	Albumin/Globulin
000292	AKID	1	D	Albumin	Laboratory Test	LN	46099-8	Calcium^corrected for albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	46130-1	Prealbumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	47558-2	Albumin/Protein.total
000292	AKID	1	D	Albumin	Laboratory Test	LN	49002-9	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	49023-5	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	50209-6	Albumin^supine
000292	AKID	1	D	Albumin	Laboratory Test	LN	51190-7	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	51693-0	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	53229-1	Prealbumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	53529-4	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	53530-2	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	53531-0	Albumin



**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000292	AKID	1	D	Albumin	Laboratory Test	LN	53532-8	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	54346-2	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	54347-0	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	54464-3	Albumin/Protein.total
000292	AKID	1	D	Albumin	Laboratory Test	LN	56153-0	Albumin.serum/Albumin.Periton fld
000292	AKID	1	D	Albumin	Laboratory Test	LN	57369-1	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	56553-1	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	58447-4	Microalbumin/Creatinine ratio panel
000292	AKID	1	D	Albumin	Laboratory Test	LN	58448-2	Albumin ug/min
000292	AKID	1	D	Albumin	Laboratory Test	LN	58807-9	Conalbumin native (nGal d) 3 Ab.IgE
000292	AKID	1	D	Albumin	Laboratory Test	LN	59159-4	Albumin/Creatinine
000292	AKID	1	D	Albumin	Laboratory Test	LN	7444-3	Lactalbumin Ab.IgG
000292	AKID	1	D	Albumin	Laboratory Test	LN	7445-0	Lactalbumin alpha Ab.IgE
000292	AKID	1	D	Albumin	Laboratory Test	LN	7446-8	Lactalbumin basophil bound Ab
000292	AKID	1	D	Albumin	Laboratory Test	LN	61151-7	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	61152-5	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	61195-4	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	61196-2	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	61213-5	Lactalbumin alpha Ab.IgE
000292	AKID	1	D	Albumin	Laboratory Test	LN	62234-0	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	62235-7	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	7556-4	Ovalbumin Ab.IgE
000292	AKID	1	D	Albumin	Laboratory Test	LN	6782-7	IgG/Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	6793-4	Prealbumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	6941-9	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	6942-7	Albumin
000292	AKID	1	D	Albumin	Laboratory Test	LN	9318-7	Albumin/Creatinine
000292	AKID	1	D	Albumin	Laboratory Test	LN	9405-2	Albumin/Globulin
000292	AKID	1	D	Albumin	Laboratory Test	LN	9406-0	Albumin/Globulin
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	I9	791.0	Proteinuria (Albuminuria)
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	I10	R80.9	Proteinuria NOS (Albuminuria NOS)
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	I10	R80.1	Persistent Proteinuria, Unspecified
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	I10	R80.8	Other Proteinuria
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	SNM	274769005	albuminuria
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	SNM	397748008	hypertension with albuminuria
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	SNM	167582007	urine microalbumin positive
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	SNM	32482005	orthostatic proteinuria
000291	AKID	1	D	Albuminuria	Condition / Diagnosis / Problem	SNM	48160003	lordotic proteinuria
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314445006	average night interval systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	407556006	lying systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314439003	maximum systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314448008	maximum 24 hour systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314444005	maximum day interval systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314443004	maximum night interval systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314438006	minimum systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314447003	minimum 24 hour systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314441002	minimum day interval systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	314442009	minimum night interval systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	407554009	sitting systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	400974009	standing systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	72313002	systolic arterial pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	399304008	systolic blood pressure on admission (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	315612005	target systolic blood pressure (observable entity)
000293	AKID	1	N	Blood Pressure, Systolic	Physical Exam	SNM	271649006	systolic blood pressure
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	315613000	target diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	407557002	lying diastolic blood pressure (observable entity)

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314451001	minimum diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314452008	maximum diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314453003	average diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	251073000	invasive diastolic arterial pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	407555005	sitting diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	400975005	standing diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	163031004	on examination - Diastolic blood pressure reading (finding)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	174255007	non-invasive diastolic arterial pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314465004	24 hour diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	413605002	average home diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314456006	minimum 24 hour diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314462001	average 24 hour diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314459004	maximum 24 hour diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314461008	average day interval diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314460009	average night interval diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314458007	maximum day interval diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314457002	maximum night interval diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314455005	minimum night interval diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	314454009	minimum day interval diastolic blood pressure (observable entity)
000294	AKID	1	N	Blood Pressure, Diastolic	Physical Exam	SNM	271650006	diastolic blood pressure (observable entity)
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185673004	blood pressure abnormal - 1st recall
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185674005	blood pressure abnormal - 2nd recall
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185675006	blood pressure abnormal - 3rd recall
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185665008	BP screening - first call
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185669002	BP screening - first recall
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185670001	BP screening - second recall
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185666009	BP screening - second call
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185667000	BP screening - third call
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185671002	BP screening - third recall
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	135840009	blood pressure monitoring
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	385846000	blood pressure taking management (procedure)
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	314463006	24 hour blood pressure (observable entity)
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	6797001	mean blood pressure (observable entity)
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	61310001	nutrition education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	11816003	diet education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	438578000	dietary education for renal disorder
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	312853008	special diet education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	266724001	weight-reducing diet education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	284352003	obesity diet education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	410178001	special diet management
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	410176002	special diet assessment
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	410289001	exercises education, guidance, and counseling
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	410289001	exercise status screening
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	410289001	recommendation to exercise
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	39155009	hypertension education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	443402002	lifestyle education regarding hypertension
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	183856001	referral to hypertension clinic
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	49239009	biofeedback training in regulation of blood pressure for essential hypertension
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	183063000	low salt diet education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	185671002	blood pressure recorded by patient at home
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	10189731000046100	Anti-hypertensive diet education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	10189741000046109	Anti-hypertensive diet management
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	10189751000046107	Anti-hypertensive diet assessment
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	10189761000046105	Anti-hypertensive exercise education
000295	AKID	1	N	Blood Pressure Plan of Care	Care Plan	SNM	10189771000046103	Review of home blood pressure log

**PCPI eSpecification**  
**ADULT KIDNEY DISEASE**  
**AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197475	Chlorothiazide 250 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	309198	Chlorothiazide 50 MG/ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197476	Chlorothiazide 500 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	541298	Chlotride 500 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213443	Diuril 250 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213439	Diuril 50 MG/ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213447	Diuril 500 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197497	Chlorthalidone 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197498	Chlorthalidone 15 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197499	Chlorthalidone 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197500	Chlorthalidone 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831703	Hydone Tablet 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831701	Hydone Tablet 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201263	Hygroton 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	214082	Hygroton 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201262	Hygroton 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	214081	Thalitone 15 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	214083	Thalitone 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	310813	HCTZ 10 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197769	HCTZ 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	314020	HCTZ 100 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199903	HCTZ 12.5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	429503	HCTZ 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	310798	HCTZ 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197770	HCTZ 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207936	Esidrix 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207942	Esidrix 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207943	Ezide 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207937	Hydro Par 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207944	Hydro Par 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	542850	Hydrocot 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207935	HydroDIURIL 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207938	HydroDIURIL 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207945	HydroDIURIL 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	542854	Hydrokraft 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207946	Loqua 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207939	Oretic 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207947	Oretic 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198110	Polythiazide 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198111	Polythiazide 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198112	Polythiazide 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208716	Renese 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208717	Renese 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208719	Renese 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197815	Indapamide 1.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197816	Indapamide 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206945	Lozol 1.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206946	Lozol 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197977	Metolazone 0.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197978	Metolazone 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197979	Metolazone 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311671	Metolazone 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	93382	Mykrox 0.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207276	Zaroxolyn 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207271	Zaroxolyn 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207272	Zaroxolyn 5 MG Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	250660	Bumetanide 0.2 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197417	Bumetanide 0.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197418	Bumetanide 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197419	Bumetanide 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104222	Bumetanide 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205488	Bumex 0.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205489	Bumex 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205490	Bumex 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	251308	Furosemide 1 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197730	Furosemide 10 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	630032	Furosemide 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	310429	Furosemide 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104220	furosemide 20 MG per 5 ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313988	Furosemide 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	248657	Furosemide 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199610	Furosemide 500 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197732	Furosemide 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	542678	Furocot 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205726	Lasix 10 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200801	Lasix 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200809	Lasix 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205732	Lasix 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205728	Lo-Aqua 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	630035	Salix - substance 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	645036	Salix - substance 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198369	torsemide 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198370	torsemide 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	250044	torsemide 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198371	torsemide 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198372	torsemide 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208076	Demadex 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208080	Demadex 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208081	Demadex 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208082	Demadex 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	977882	Midamor 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	977887	Amiloride Hydrochloride 1 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	977880	Amiloride Hydrochloride 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198312	Triamterene 100 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198313	Triamterene 50 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208674	Dyrenium 100 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208675	Dyrenium 50 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	351258	eplerenone 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	351256	eplerenone 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	351257	eplerenone 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	402106	Inspra 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	402105	Inspra 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104231	spironolactone 10 MG per 5 ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198222	Spironolactone 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313096	Spironolactone 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104232	spironolactone 25 MG per 5 ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104230	spironolactone 5 MG per 5 ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198223	Spironolactone 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104233	spironolactone 50 MG per 5 ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200825	Aldactone 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200820	Aldactone 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200817	Aldactone 50 MG Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197379	Atenolol 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197380	Atenolol 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	755528	atenolol 25 MG per 5 ML Syrup
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197381	Atenolol 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	211773	Senormin 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201322	Tenormin 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	150750	Tenormin 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	152414	Tenormin 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	261397	Betaxolol 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	261398	Betaxolol 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213731	Kerlone 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	141882	Kerlone 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	865154	Bisoprolol Fumarate 1.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854901	Bisoprolol Fumarate 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	865155	Bisoprolol Fumarate 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	865157	Bisoprolol Fumarate 3.75 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854905	Bisoprolol Fumarate 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	865159	Bisoprolol Fumarate 7.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854903	Zebeta 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854907	Zebeta 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866514	Metoprolol Tartrate 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866511	Metoprolol Tartrate 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866924	metoprolol tartrate 25 MG (as metoprolol succinate 23.75 MG) Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866513	Lopressor 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866516	Lopressor 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866513	Lopressor 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866516	Lopressor 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866415	Metoprolol Tartrate 100 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866419	metoprolol tartrate 200 MG (as metoprolol succinate 190 MG) 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866422	Metoprolol Tartrate 200 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866427	metoprolol tartrate 25 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866430	Metoprolol Tartrate 25 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866436	metoprolol tartrate 50 MG (as metoprolol succinate 47.5 MG) 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866439	Metoprolol Tartrate 50 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866414	24 HR Toprol XL 100 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866421	24 HR Toprol XL 200 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866429	24 HR Toprol XL 25 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866416	Toprol 100 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866423	Toprol 200 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866431	Toprol 25 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866440	Toprol 50 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	866438	Toprol XL 50 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198004	Nadolol 120 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198005	Nadolol 160 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198006	Nadolol 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198007	Nadolol 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198008	Nadolol 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206968	Nadolol 160 MG Oral Tablet [Corgard]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201337	Nadolol 40 MG Oral Tablet [Corgard]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201338	Nadolol 80 MG Oral Tablet [Corgard]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208003	Bendroflumethiazide 5 MG / Nadolol 40 MG Oral Tablet [Corzide 40/5]

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208029	Bendroflumethiazide 5 MG / Nadolol 80 MG Oral Tablet [Corzide 80/5]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856448	Propranolol Hydrochloride 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856713	Propranolol Hydrochloride 160 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856719	Propranolol Hydrochloride 2 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856457	Propranolol Hydrochloride 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856724	propranolol hydrochloride 20 MG per 5 ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856519	Propranolol Hydrochloride 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856733	Propranolol Hydrochloride 40 MG per 5 ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856704	Propranolol Hydrochloride 5 MG per 5 ML Oral Syrup
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856703	Propranolol Hydrochloride 50 MG per 5 ML Oral Syrup
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856556	Propranolol Hydrochloride 60 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856735	Propranolol Hydrochloride 80 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856578	Propranolol Hydrochloride 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856712	Propranolol Hydrochloride 80 MG per 5 ML Oral Syrup
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856737	Propranolol Hydrochloride 80 MG/ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856739	Propranolol Hydrochloride 90 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856450	Inderal 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856508	Inderal 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856521	Inderal 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856557	Inderal 60 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856579	Inderal 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856459	Pronol 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856528	Pronol 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856460	propranolol hydrochloride 120 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856463	Propranolol Hydrochloride 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856481	propranolol hydrochloride 160 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856484	Propranolol Hydrochloride 160 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856535	propranolol hydrochloride 60 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856538	Propranolol Hydrochloride 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856569	propranolol hydrochloride 80 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856572	Propranolol Hydrochloride 80 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856464	Inderal 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856485	Inderal 160 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856539	Inderal 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856573	Inderal 80 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856462	Inderal LA 120 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856483	Inderal LA 160 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856537	Inderal LA 60 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856571	Inderal LA 80 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856472	InnoPran 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856577	InnoPran 80 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	856471	InnoPran XL 120 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198284	Timolol 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198285	Timolol 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198286	Timolol 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201340	Blocadren 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208576	Blocadren 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208575	Blocadren 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998693	Acebutolol Hydrochloride 100 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998689	Acebutolol Hydrochloride 200 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998685	Acebutolol Hydrochloride 400 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998695	Acebutolol Hydrochloride 400 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998691	Sectral 200 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998687	Sectral 400 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	312254	Penbutolol 20 MG Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207367	Levitol 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198104	Pindolol 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199277	Pindolol 15 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198105	Pindolol 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208140	Visken 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200857	Visken 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200032	carvedilol 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200033	carvedilol 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	686924	carvedilol 3.125 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200031	carvedilol 6.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860510	carvedilol phosphate 10 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860513	carvedilol phosphate 10 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860516	carvedilol phosphate 20 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860519	carvedilol phosphate 20 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860522	carvedilol phosphate 40 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860525	carvedilol phosphate 40 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860532	carvedilol phosphate 80 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860535	carvedilol phosphate 80 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860512	24 HR Coreg 10 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860518	24 HR Coreg 20 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860524	24 HR Coreg 40 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860534	24 HR Coreg 80 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860514	Coreg 10 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	212389	Coreg 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860520	Coreg 20 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	212390	Coreg 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	686926	Coreg 3.125 Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860526	Coreg 40 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	212388	Coreg 6.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	860536	Coreg 80 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896758	Labetalol hydrochloride 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896762	Labetalol hydrochloride 200 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896766	Labetalol hydrochloride 300 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896983	Labetalol hydrochloride 400 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896987	Labetalol hydrochloride 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896760	Normodyne 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896764	Normodyne 200 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896768	Normodyne 300 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896777	Trandate 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896781	Trandate 200 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	896783	Trandate 300 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308607	benazepril 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308609	benazepril 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308612	benazepril 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308962	Captopril 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308963	Captopril 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	317173	Captopril 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308964	Captopril 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201370	Captopril 12.5 MG Oral Tablet [Capoten]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	210994	Capoten 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	210994	Capoten 12.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201372	Capoten 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201374	Capoten 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858914	Enalapril Maleate 10 MG Chewable Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858920	Enalapril Maleate 2.5 MG Chewable Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858938	Enalapril Maleate 5 MG Chewable Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858813	Enalapril Maleate 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858845	Renitec 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858819	Vasotec 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858806	Vasotec 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858812	Vasotec 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858815	Vasotec 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	857169	Fosinopril Sodium 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	857183	Fosinopril Sodium 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	857187	Fosinopril Sodium 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	857171	Monopril 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	857185	Monopril 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	857189	Monopril 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	314076	Lisinopril 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311353	Lisinopril 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	314077	Lisinopril 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205326	Lisinopril 30 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197884	Lisinopril 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311354	Lisinopril 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206765	Prinivil 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206763	Prinivil 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206766	Prinivil 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206770	Prinivil 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206764	Prinivil 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104377	Zestril 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104375	Zestril 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104378	Zestril 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213482	Zestril 30 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206771	Zestril 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104376	Zestril 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311734	moexipril 15 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311735	moexipril 7.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206277	Univasc 15 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206313	Univasc 7.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854984	Perindopril Erbumine 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854988	Perindopril Erbumine 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854925	Perindopril Erbumine 8 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854986	Aceon 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854990	Aceon 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	854927	Aceon 8 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	312748	quinapril (as quinapril hydrochloride) 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	312749	quinapril (as quinapril hydrochloride) 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	314203	quinapril (as quinapril hydrochloride) 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	312750	quinapril (as quinapril hydrochloride) 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207892	Accupril 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207893	Accupril 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207895	Accupril 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207891	Accupril 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845488	Ramipril 1.25 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	401965	Ramipril 1.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	261962	Ramipril 10 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	401968	Ramipril 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198188	Ramipril 2.5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	251856	Ramipril 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198189	Ramipril 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	251857	Ramipril 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845489	Altace 1.25 MG Oral Capsule



**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	730511	Altace 1.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	260333	Altace 10 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	730512	Altace 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104384	Altace 2.5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	730513	Altace 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104385	Altace 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	730514	Altace 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199622	trandolapril 0.5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199816	trandolapril 1 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199353	trandolapril 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199817	trandolapril 2 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199351	trandolapril 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	210671	Mavik 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	210672	Mavik 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	210673	Mavik 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	639537	candesartan cilexetil 32 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153822	candesartan cilexetil 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153823	candesartan cilexetil 8 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	639539	Atacand 16 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	639543	Atacand 32 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	577785	Atacand 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	577787	Atacand 8 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	389185	eprosartan 300 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	310139	eprosartan 400 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	310140	eprosartan 600 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	261300	Teveten 400 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	261301	Teveten 600 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200095	irbesartan 150 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200096	irbesartan 300 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	200094	irbesartan 75 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153666	Avapro 150 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153667	Avapro 300 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153665	Avapro 75 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	979480	Losartan Potassium 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	979485	Losartan Potassium 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	979492	Losartan Potassium 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	979482	Cozaar 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	979487	Cozaar 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	979494	Cozaar 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	401971	Olmesartan medoxomil 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349401	Olmesartan medoxomil 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349405	Olmesartan medoxomil 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349373	Olmesartan medoxomil 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	575927	Olmesartan medoxomil 20 MG [Benicar]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	575928	Olmesartan medoxomil 40 MG [Benicar]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	575926	Olmesartan medoxomil 5 MG [Benicar]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	282755	telmisartan 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205304	telmisartan 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205305	telmisartan 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	284531	Micardis 20 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213431	Micardis 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	213432	Micardis 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199919	valsartan 160 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349201	valsartan 160 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349200	valsartan 320 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153077	valsartan 40 MG Oral Capsule

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349483	valsartan 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199850	valsartan 80 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	349199	valsartan 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153080	Diovan 160 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	351762	Diovan 160 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	352001	Diovan 320 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	352274	Diovan 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	153079	Diovan 80 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	351761	Diovan 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830872	diltiazem hydrochloride 120 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830861	diltiazem hydrochloride 120 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830874	diltiazem hydrochloride 120 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831150	Diltiazem Hydrochloride 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831117	Diltiazem Hydrochloride 120 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831054	Diltiazem Hydrochloride 120 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830845	diltiazem hydrochloride 180 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830877	diltiazem hydrochloride 180 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831233	Diltiazem Hydrochloride 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831230	Diltiazem Hydrochloride 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831229	Diltiazem Hydrochloride 180 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833716	diltiazem hydrochloride 200 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845214	Diltiazem Hydrochloride 200 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830837	diltiazem hydrochloride 240 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830879	diltiazem hydrochloride 240 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831274	Diltiazem Hydrochloride 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831271	Diltiazem Hydrochloride 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833217	Diltiazem Hydrochloride 30 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830801	diltiazem hydrochloride 300 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830882	diltiazem hydrochloride 300 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831313	Diltiazem Hydrochloride 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831312	Diltiazem Hydrochloride 300 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830795	Diltiazem Hydrochloride 360 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830897	diltiazem hydrochloride 360 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831339	Diltiazem Hydrochloride 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845184	Diltiazem Hydrochloride 360 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831359	diltiazem hydrochloride 420 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830900	diltiazem hydrochloride 420 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831351	Diltiazem Hydrochloride 420 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831350	Diltiazem Hydrochloride 420 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830865	diltiazem hydrochloride 60 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833707	diltiazem hydrochloride 60 MG 12 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830922	Diltiazem Hydrochloride 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830979	Diltiazem Hydrochloride 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831012	Diltiazem Hydrochloride 60 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831103	Diltiazem Hydrochloride 60 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830869	diltiazem hydrochloride 90 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833708	diltiazem hydrochloride 90 MG 12 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831022	Diltiazem Hydrochloride 90 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831021	Diltiazem Hydrochloride 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831102	Diltiazem Hydrochloride 90 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	849860	Diltiazem Malate 240 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830873	12 HR Cardizem 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830867	12 HR Cardizem 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830871	12 HR Cardizem 90 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830863	24 HR Cardizem 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830876	24 HR Cardizem 120 MG Extended Release Tablet

**PCPI eSpecification**  
**ADULT KIDNEY DISEASE**  
**AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830847	24 HR Cardizem 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830878	24 HR Cardizem 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830839	24 HR Cardizem 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830880	24 HR Cardizem 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830803	24 HR Cardizem 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830883	24 HR Cardizem 300 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830798	24 HR Cardizem 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830898	24 HR Cardizem 360 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	830902	24 HR Cardizem 420 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831226	24 HR Cartia 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831255	24 HR Cartia 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831309	24 HR Cartia 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831338	24 HR Cartia 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831224	24 HR Dilacor 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831254	24 HR Dilacor 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831305	24 HR Dilacor 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831215	24 HR Diltiazem Hydrochloride 120 MG Extended Release Capsule [Dilt]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831252	24 HR Diltiazem Hydrochloride 180 MG Extended Release Capsule [Dilt]"
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831285	24 HR Diltiazem Hydrochloride 240 MG Extended Release Capsule [Dilt]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831337	24 HR Diltiazem Hydrochloride 300 MG Extended Release Capsule [Dilt]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831302	24 HR Diltiazem Hydrochloride 240 MG Extended Release Capsule [Diltia]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831209	24 HR Diltiazem Hydrochloride 120 MG Extended Release Capsule [Diltia]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	848524	24 HR Diltia XT 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	848524	24 HR Diltzac 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833703	24 HR Diltzac 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833704	24 HR Diltzac 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833705	24 HR Diltzac 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833706	24 HR Diltzac 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831196	24 HR Taztia 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831248	24 HR Taztia 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831300	24 HR Taztia 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831325	24 HR Taztia 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831349	24 HR Taztia 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833694	24 HR Tiamate 120 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833695	24 HR Tiamate 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833696	24 HR Tiamate 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831193	24 HR Tiazac 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831244	24 HR Tiazac 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831296	24 HR Tiazac 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831323	24 HR Tiazac 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831323	24 HR Tiazac 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845176	Cardizem 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845180	Cardizem 120 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831055	Cardizem 120 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845175	Cardizem 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845181	Cardizem 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845174	Cardizem 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845182	Cardizem 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	833219	Cardizem 30 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845173	Cardizem 300 MG Extended Release Capsule

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845183	Cardizem 300 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845172	Cardizem 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845185	Cardizem 360 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845186	Cardizem 420 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845177	Cardizem 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	834393	Cardizem 60 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845178	Cardizem 90 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831137	Cardizem 90 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845192	Cartia 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831242	Cartia 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831288	Cartia 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831321	Cartia 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845191	Dilacor 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845197	Dilacor 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845202	Dilacor 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845190	Dilt 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845196	Dilt 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845198	Dilt 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845205	Dilt 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845189	Diltia 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845195	Diltia 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845201	Diltia 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831172	Diltzac 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831240	Diltzac 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831282	Diltzac 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831319	Diltzac 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831345	Diltzac 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845188	Taztia 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845194	Taztia 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845200	Taztia 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845204	Taztia 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845207	Taztia 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	846148	Tecczem Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831119	Tiamate 120 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831232	Tiamate 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831273	Tiamate 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845187	Tiazac 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845193	Tiazac 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845199	Tiazac 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845203	Tiazac 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845206	Tiazac 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	831360	Tiazac 420 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845208	Tiazac 420 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897666	Verapamil hydrochloride 120 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901438	Verapamil hydrochloride 160 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	898340	Verapamil hydrochloride 180 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901446	Verapamil hydrochloride 240 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897722	Verapamil hydrochloride 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901450	verapamil hydrochloride 40 MG per 5 ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897683	Verapamil hydrochloride 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897635	verapamil 180 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897646	verapamil 240 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897584	verapamil hydrochloride 100 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897587	Verapamil hydrochloride 100 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901434	verapamil hydrochloride 120 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897612	verapamil hydrochloride 120 MG 24HR Extended Release Capsule

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897615	Verapamil hydrochloride 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897659	Verapamil hydrochloride 120 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897618	verapamil hydrochloride 180 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897621	Verapamil hydrochloride 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897640	Verapamil hydrochloride 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897590	verapamil hydrochloride 200 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897593	Verapamil hydrochloride 200 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897624	verapamil hydrochloride 240 MG 24HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897627	Verapamil hydrochloride 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897649	Verapamil hydrochloride 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897596	verapamil hydrochloride 300 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897599	Verapamil hydrochloride 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897630	verapamil hydrochloride 360 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897633	Verapamil hydrochloride 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897719	Verapamil hydrochloride 40 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901448	Verapamil hydrochloride 400 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897635	verapamil 180 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897646	verapamil 240 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897584	verapamil hydrochloride 100 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897587	Verapamil hydrochloride 100 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901434	verapamil hydrochloride 120 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897612	verapamil hydrochloride 120 MG 24HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897615	Verapamil hydrochloride 120 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897659	Verapamil hydrochloride 120 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897666	Verapamil hydrochloride 120 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901438	Verapamil hydrochloride 160 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897618	verapamil hydrochloride 180 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897621	Verapamil hydrochloride 180 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897640	Verapamil hydrochloride 180 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	898340	Verapamil hydrochloride 180 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897590	verapamil hydrochloride 200 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897593	Verapamil hydrochloride 200 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897624	verapamil hydrochloride 240 MG 24HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897627	Verapamil hydrochloride 240 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897649	Verapamil hydrochloride 240 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901446	Verapamil hydrochloride 240 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897596	verapamil hydrochloride 300 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897599	Verapamil hydrochloride 300 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897630	verapamil hydrochloride 360 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897633	Verapamil hydrochloride 360 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897719	Verapamil hydrochloride 40 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897722	Verapamil hydrochloride 40 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901450	verapamil hydrochloride 40 MG per 5 ML Oral Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	901448	Verapamil hydrochloride 400 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	897683	Verapamil hydrochloride 80 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	757675	Amlodipine 2.5 MG Disintegrating Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	757676	Amlodipine 5 MG Disintegrating Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	757674	Amlodipine 10 MG Disintegrating Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308135	amlodipine (as amlodipine besylate) 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	308136	amlodipine (as amlodipine besylate) 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197361	amlodipine (as amlodipine besylate) 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	212575	Norvasc 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	212542	Norvasc 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	212549	Norvasc 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	402695	Felodipine 10 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	700745	Felodipine 10 MG Extended Release Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	402698	Felodipine 2.5 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197692	Felodipine 2.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	402696	felodipine 5 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	358334	Felodipine 5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104420	24 HR Plendil 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	152933	24 HR Plendil 2.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104419	24 HR Plendil 5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844418	Plendil 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844437	Plendil 2.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844417	Plendil 5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	562518	isradipine 10 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311202	Isradipine 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197848	Isradipine 2.5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199757	Isradipine 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	562520	isradipine 5 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311203	Isradipine 5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197849	Isradipine 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885733	24 HR Dynacirc 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885735	24 HR Dynacirc 5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885734	Dynacirc 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206935	Dynacirc 2.5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885736	Dynacirc 5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206934	Dynacirc 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858587	nicardipine hydrochloride 30 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858590	Nicardipine hydrochloride 30 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858580	nicardipine hydrochloride 45 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858584	Nicardipine hydrochloride 45 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858593	nicardipine hydrochloride 60 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	858596	Nicardipine hydrochloride 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	250206	nifedipine 10 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	248708	nifedipine 10 MG 12 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844748	Nifedipine 10 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844741	Nifedipine 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	249620	nifedipine 20 MG 12 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844745	Nifedipine 20 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	246262	Nifedipine 20 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	227058	nifedipine 30 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198034	nifedipine 30 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844724	Nifedipine 30 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	491070	Nifedipine 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	250384	nifedipine 40 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844750	Nifedipine 40 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	227059	nifedipine 60 MG 24 HR Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198035	nifedipine 60 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844725	Nifedipine 60 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	491078	Nifedipine 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198036	nifedipine 90 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	491086	Nifedipine 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	672916	24 HR Adalat 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	672917	24 HR Adalat 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	672918	24 HR Adalat 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	672921	24 HR Afeditab CR 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	880433	24 HR Nifediac CC 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	541603	24 HR Nifediac CC 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	880437	24 HR Nifediac CC 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	360394	24 HR Nifedical 30 MG Extended Release Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	351438	24 HR Nifedical 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207772	24 HR Procardia 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207773	24 HR Procardia 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	207774	24 HR Procardia 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845004	Adalat 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845005	Adalat 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845006	Adalat 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	672920	Afeditab CR 30 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845007	Afeditab CR 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845008	Afeditab CR 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	880434	Nifediac 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844923	Nifediac 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	880438	Nifediac 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844846	Nifedical 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844830	Nifedical 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844584	Procardia 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844585	Procardia 60 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844586	Procardia 90 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311983	nisoldipine 10 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	562154	Nisoldipine 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763519	nisoldipine 17 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845095	Nisoldipine 17 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311984	nisoldipine 20 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	562514	Nisoldipine 20 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763574	nisoldipine 25.5 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845097	Nisoldipine 25.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311985	nisoldipine 30 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	562515	Nisoldipine 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763589	nisoldipine 34 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845101	Nisoldipine 34 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	360344	nisoldipine 40 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311986	Nisoldipine 40 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	790489	nisoldipine 8.5 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763497	Nisoldipine 8.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	672922	24 HR Sular 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763521	24 HR Sular 17 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	597921	24 HR Sular 20 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763576	24 HR Sular 25.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	597922	24 HR Sular 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763591	24 HR Sular 34 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	597923	24 HR Sular 40 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	790840	24 HR Sular 8.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845009	Sular 10 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845096	Sular 17 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844942	Sular 20 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844942	Sular 25.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844943	Sular 30 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	845102	Sular 34 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	844944	Sular 40 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	763499	Sular 8.5 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197625	Doxazosin 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197626	Doxazosin 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	636360	doxazosin 4 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	389131	Doxazosin 4 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197627	Doxazosin 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	636361	doxazosin 8 MG 24 HR Extended Release Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	389166	Doxazosin 8 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197628	Doxazosin 8 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104367	Cardura 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104368	Cardura 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	631240	Cardura 4 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	104369	Cardura 4 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	631243	Cardura 8 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	205544	Cardura 8 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199796	Prazosin 0.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	312593	Prazosin 1 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199797	Prazosin 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	312594	Prazosin 2 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199798	Prazosin 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198141	Prazosin 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	199799	Prazosin 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208979	Minipress 1 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208980	Minipress 2 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208981	Minipress 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313215	terazosin (as terazosin hydrochloride) 1 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313216	terazosin (as terazosin hydrochloride) 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	260376	terazosin (as terazosin hydrochloride) 10 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313214	terazosin (as terazosin hydrochloride) 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313218	terazosin (as terazosin hydrochloride) 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313219	terazosin (as terazosin hydrochloride) 5 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	313220	terazosin (as terazosin hydrochloride) 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	1013930	12 HR Clonidine Hydrochloride 0.1 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	1013937	12 HR Clonidine Hydrochloride 0.2 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	892791	Clonidine Hydrochloride 0.025 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	1013894	Clonidine Hydrochloride 0.1 MG Enteric Coated Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885878	clonidine hydrochloride 0.1 MG/ML (clonidine 0.09 MG/ML) 24HR Extended Release Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885879	Clonidine Hydrochloride 0.1 MG/ML Extended Release Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885880	clonidine hydrochloride 0.2 MG (clonidine 0.17 MG) 24HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885881	Clonidine Hydrochloride 0.2 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	892795	Clonidine Hydrochloride 0.25 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885882	clonidine hydrochloride 0.3 MG (clonidine 0.26 MG) 24HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	885883	Clonidine Hydrochloride 0.3 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884173	clonidine hydrochloride 100 MCG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884221	clonidine hydrochloride 100 MCG/ML Injectable Solution
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884185	clonidine hydrochloride 200 MCG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884189	clonidine hydrochloride 300 MCG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	1013934	12 HR Kapvay 0.1 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	1013939	12 HR Kapvay 0.2 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884175	Catapres 0.1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884187	Catapres 0.2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	884191	Catapres 0.3 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998673	Catapres-TTS-1 0.1 MG/Day Weekly Transdermal Patch
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998677	Catapres-TTS-2 0.2 MG/Day Weekly Transdermal Patch
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998681	Catapres-TTS-3 0.3 MG/Day Weekly Transdermal Patch
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	998671	clonidine hydrochloride 0.1 MG/Day Weekly Transdermal Patch
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197956	Methyl dopa 250 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197957	Methyl dopa 50 MG/ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197958	Methyl dopa 500 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	311645	Methyl dopa 250 MG Extended Release Tablet



**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	411773	Methyldopa 350 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	411774	Methyldopa 250 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	411775	Methyldopa 175 MG Extended Release Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201355	Aldomet 250 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201361	Aldomet 50 MG/ML Oral Suspension
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201358	Aldomet 500 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198196	Reserpine 0.1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	198197	Reserpine 0.25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	315197	Reserpine 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	429105	Reserpine 0.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208085	Hydropres-25 Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	208091	Hydropres-50 Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197745	Guanfacine 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197746	Guanfacine 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862006	24 HR Guanfacine 1 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862013	24 HR Guanfacine 2 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862015	24 HR Guanfacine 2 MG Extended Release Tablet [Intuniv]
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862019	24 HR Guanfacine 3 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862025	24 HR Guanfacine 4 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862011	Guanfacine 1 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862016	Guanfacine 2 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862022	Guanfacine 3 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862028	Guanfacine 4 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862010	Intuniv 1 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862012	Intuniv 1 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862012	Intuniv 2 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862017	Intuniv 2 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862021	Intuniv 3 MG 24 HR Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862023	Intuniv 3 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	862029	Intuniv 4 MG Extended Release Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206412	Tenex 1 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	206413	Tenex 2 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905199	Hydralazine Hydrochloride 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905222	Hydralazine Hydrochloride 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905225	Hydralazine Hydrochloride 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905395	Hydralazine Hydrochloride 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	966620	Hydralazine Hydrochloride 50 MG Oral Capsule
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905201	Apresoline 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905224	Apresoline 100 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905227	Apresoline 25 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	905397	Apresoline 50 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197986	Minoxidil 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197987	Minoxidil 2.5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	197776	Minoxidil 5 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201350	Loniten 10 MG Oral Tablet
000296	AKID	1	N	Single Agent Anti Hypertensive	Medication	RxNorm	201348	Loniten 2.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898342	Amlodipine 10 MG / Benazepril hydrochloride 20 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898346	Amlodipine 10 MG / Benazepril hydrochloride 40 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898350	Amlodipine 2.5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898353	Amlodipine 5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898356	Amlodipine 5 MG / Benazepril hydrochloride 20 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898359	Amlodipine 5 MG / Benazepril hydrochloride 40 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898344	Lotrel 10/20 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898348	Lotrel 10/40 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898352	Lotrel 2.5/10 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898355	Lotrel 5/10 Oral Capsule

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898358	Lotrel 5/20 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898361	Lotrel 5/40 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858618	Enalapril Maleate 5 MG / Felodipine 2.5 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858621	Enalapril Maleate 5 MG / Felodipine 5 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858884	Lexxel 5/2.5 Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858892	Lexxel 5/5 Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897781	trandolapril 1 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897778	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897783	trandolapril 2 MG / verapamil hydrochloride 180 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	901451	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897786	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897844	trandolapril 2 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897847	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897853	trandolapril 4 MG / Verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897856	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897782	Tarka 1/240 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897785	Tarka 2/180 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897846	Tarka 2/240 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897855	Tarka 4/240 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897780	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 1/240]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897787	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet [Tarka 2/180]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897848	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 2/240]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897857	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 4/240]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898362	benazepril hydrochloride 10 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898367	benazepril hydrochloride 20 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898372	Benazepril hydrochloride 20 MG / Hydrochlorothiazide 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898378	Benazepril hydrochloride 5 MG / Hydrochlorothiazide 6.25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898371	Lotensin HCT (benazepril 20 MG / HCTZ 12.5 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898376	Lotensin HCT (benazepril 20 MG / HCTZ 25 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898366	Lotensin HCT 10/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898382	Lotensin HCT 5/6.25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	104370	captopril 25 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197436	captopril 25 MG / HCTZ 15 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197437	captopril 25 MG / HCTZ 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197438	captopril 50 MG / HCTZ 15 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197439	captopril 50 MG / HCTZ 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	211053	Capozide 25/15 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	211072	Capozide 25/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	790297	Capozide 50/15 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	790296	Capozide 50/25 Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858828	enalapril maleate 10 MG / HCTZ 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858921	enalapril maleate 20 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858935	enalapril maleate 5 MG / HCTZ 12.5 MG Chewable Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858824	enalapril maleate 5 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858827	Vaseretic (enalapril maleate 5 MG / HCTZ 12.5 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858830	Vaseretic 10/25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857166	fosinopril sodium 10 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857174	fosinopril sodium 20 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857182	Monopril-HCT 10/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	857178	Monopril-HCT 20/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197885	HCTZ 12.5 MG / lisinopril 10 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197886	HCTZ 12.5 MG / lisinopril 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197887	HCTZ 25 MG / lisinopril 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1001394	Hydrochlorothiazide 12.5 MG / Lisinopril 5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207963	Prinzide (HCTZ 12.5 MG / lisinopril 20 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207961	Prinzide (lisinopril 10 MG / HCTZ 12.5 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207965	Prinzide (lisinopril 20 MG / HCTZ 25 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	207965	Zestoretic 10/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823986	Zestoretic 10/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823982	Zestoretic 20/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823971	Zestoretic 20/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	349443	HCTZ 12.5 MG / moexipril 15 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310795	HCTZ 12.5 MG / moexipril 7.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310805	HCTZ 25 MG / moexipril 15 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	891618	Uniretic 15/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	891626	Uniretic 15/25 (moexipril / HCTZ) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	891622	Uniretic 7.5/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310796	HCTZ 12.5 MG / quinapril 10 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310797	HCTZ 12.5 MG / quinapril 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310809	HCTZ 25 MG / quinapril 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809854	Accuretic 10/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809858	Accuretic 20/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	882559	Accuretic 20/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	991549	Quinaretic 10/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	991553	Quinaretic 20/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	991557	Quinaretic 20/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	578325	candesartan cilexetil 16 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	578330	candesartan cilexetil 32 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	802749	candesartan cilexetil 32 MG / HCTZ 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	805863	Atacand HCT 16/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	805859	Atacand HCT 32/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	805855	Atacand HCT 32/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	351292	eprosartan 600 MG / HCTZ 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	351293	eprosartan 600 MG / HCTZ 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	352335	Teveten HCT (eprosartan 600 MG / HCTZ 12.5 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	352336	Teveten HCT (eprosartan 600 MG / HCTZ 25 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310792	HCTZ 12.5 MG / irbesartan 150 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310793	HCTZ 12.5 MG / irbesartan 300 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	485471	HCTZ 25 MG / irbesartan 300 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823934	Avalide 150/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823938	Avalide 300/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	823942	Avalide 300/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979464	HCTZ 12.5 MG / losartan potassium 100 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979468	HCTZ 12.5 MG / losartan potassium 50 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979471	HCTZ 25 MG / losartan potassium 100 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979466	Hyzaar 100/12.5 Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979473	Hyzaar 100/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	979470	Hyzaar 50/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	403853	HCTZ 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	403854	HCTZ 12.5 MG / olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	403855	HCTZ 25 MG / olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	847060	Benicar HCT 20/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	847055	Benicar HCT 40/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	847042	Benicar HCT 40/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	283316	HCTZ 12.5 MG / telmisartan 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	283317	HCTZ 12.5 MG / telmisartan 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	477130	HCTZ 25 MG / telmisartan 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	749833	Micardis-HCT 40/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	749837	Micardis-HCT 80/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	749841	Micardis-HCT 80/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	200285	HCTZ 12.5 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	636042	HCTZ 12.5 MG / valsartan 320 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	200284	HCTZ 12.5 MG / valsartan 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	349353	HCTZ 25 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	636045	HCTZ 25 MG / valsartan 320 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809018	Diovan HCT 160/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809022	Diovan HCT 160/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809026	Diovan HCT 320/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809030	Diovan HCT 320/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	809014	Diovan HCT 80/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197382	Atenolol 100 MG / Chlorthalidone 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	152916	Atenolol 50 MG / Chlorthalidone 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197383	Atenolol 50 MG / Chlorthalidone 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746023	Tenoretic 100 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746030	Tenoretic 50 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854908	bisoprolol fumarate 10 MG / HCTZ 6.25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854916	bisoprolol fumarate 2.5 MG / HCTZ 6.25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854919	bisoprolol fumarate 5 MG / HCTZ 6.25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854910	Ziac 10/6.25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854918	Ziac 2.5/6.25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854921	Ziac 5/6.25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866461	HCTZ 12.5 MG / metoprolol tartrate 25 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866472	HCTZ 12.5 MG / metoprolol tartrate 50 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866479	HCTZ 25 MG / metoprolol tartrate 100 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866846	HCTZ 25 MG / metoprolol tartrate 200 MG (as metoprolol succinate 190 MG) 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866482	HCTZ 25 MG / metoprolol tartrate 50 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866491	HCTZ 50 MG / metoprolol tartrate 100 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866452	hydrochlorothiazide 12.5 MG / metoprolol tartrate 100 MG (as metoprolol succinate 95 MG) 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866456	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 100 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866465	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 25 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866476	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 50 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866455	Dutoprol 100/12.5 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866464	Dutoprol 25/12.5 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866475	Dutoprol 50/12.5 24 HR Extended Release Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866457	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 100 MG Extended Release Tablet [Dutoprol 100/12.5]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866466	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 25 MG Extended Release Tablet [Dutoprol 25/12.5]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866477	Hydrochlorothiazide 12.5 MG / Metoprolol Tartrate 50 MG Extended Release Tablet [Dutoprol 50/12.5]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866498	Lopressor HCT 100/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866506	Lopressor HCT 100/50 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866502	Lopressor HCT 50/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198000	Bendroflumethiazide 5 MG / Nadolol 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198001	Bendroflumethiazide 5 MG / Nadolol 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208003	Corzide 40/5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208029	Corzide 80/5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856398	24 HR Hydrochlorothiazide 50 MG / Propranolol Hydrochloride 120 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856401	24 HR Hydrochlorothiazide 50 MG / Propranolol Hydrochloride 160 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856412	24 HR Hydrochlorothiazide 50 MG / Propranolol Hydrochloride 80 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856422	HCTZ 25 MG / propranolol hydrochloride 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856429	HCTZ 25 MG / propranolol hydrochloride 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856393	HCTZ 50 MG / propranolol hydrochloride 120 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856406	HCTZ 50 MG / propranolol hydrochloride 160 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856417	HCTZ 50 MG / propranolol hydrochloride 80 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856426	Inderide 40/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856433	Inderide 80/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856586	Inderide LA 120/50 24 HR Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856587	Inderide LA 120/50 Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856591	Inderide LA 160/50 24 HR Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856592	Inderide LA 160/50 Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856596	Inderide LA 80/50 24 HR Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	856597	Inderide LA 80/50 Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310811	HCTZ 25 MG / timolol 10 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	491234	Timolide (HCTZ 25 MG / timolol 10 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197963	HCTZ 15 MG / methyldopa 250 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197960	HCTZ 25 MG / methyldopa 250 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197962	HCTZ 30 MG / methyldopa 500 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197961	HCTZ 50 MG / methyldopa 500 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688643	Aldoril (HCTZ 15 MG / methyldopa 250 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688645	Aldoril (HCTZ 25 MG / methyldopa 250 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688647	Aldoril (HCTZ 30 MG / methyldopa 500 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	688649	Aldoril (HCTZ 50 MG / methyldopa 500 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205364	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205365	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214094	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet [Demi-Regroton]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214095	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet [Regroton]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	237192	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197477	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213504	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet [Diupres-250]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213505	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet [Diupres-500]

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310810	HCTZ 25 MG / reserpine 0.1 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	204501	HCTZ 25 MG / reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	314018	HCTZ 50 MG / reserpine 0.1 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197771	HCTZ 50 MG / reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208084	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydro-Reserp]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208086	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydroserp]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208087	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydroserpine #1]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208088	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Hydroserpine]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208089	Hydrochlorothiazide 25 MG / Reserpine 0.125 MG Oral Tablet [Mallopress]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208090	Hydrochlorothiazide 50 MG / Reserpine 0.125 MG Oral Tablet [Hydro-Reserp]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208092	Hydrochlorothiazide 50 MG / Reserpine 0.125 MG Oral Tablet [Hydroserp]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208093	Hydrochlorothiazide 50 MG / Reserpine 0.125 MG Oral Tablet [Hydroserpine]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208085	Hydropres-25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208091	Hydropres-50 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	977950	Amiloride Hydrochloride 2.5 MG / Hydrochlorothiazide 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	977883	amiloride hydrochloride 5 MG / HCTZ 50 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	977885	Moduretic 5-50 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198224	HCTZ 25 MG / spironolactone 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198225	HCTZ 50 MG / spironolactone 50 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208112	Aldactazide 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208116	Aldactazide 50 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208113	Hydrochlorothiazide 25 MG / Spironolactone 25 MG Oral Tablet [Spironolactone Plus]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	314029	HCTZ 25 MG / triamterene 50 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198316	HCTZ 25 MG / triamterene 37.5 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310812	HCTZ 25 MG / triamterene 37.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	198314	HCTZ 25 MG / triamterene 50 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	310818	HCTZ 50 MG / triamterene 75 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	208124	Dyazide (HCTZ 25 MG / triamterene 37.5 MG) Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	93253	Maxzide-25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	93252	Maxzide-50 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	237192	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197477	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213504	Chlorothiazide 250 MG / Reserpine 0.125 MG Oral Tablet [Diupres-250]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	213505	Chlorothiazide 500 MG / Reserpine 0.125 MG Oral Tablet [Diupres-500]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205364	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	205365	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214094	Chlorthalidone 25 MG / Reserpine 0.125 MG Oral Tablet [Demi-Regroton]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	214095	Chlorthalidone 50 MG / Reserpine 0.25 MG Oral Tablet [Regroton]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197382	Atenolol 100 MG / Chlorthalidone 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	152916	Atenolol 50 MG / Chlorthalidone 12.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	197383	Atenolol 50 MG / Chlorthalidone 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746023	Tenoretic 100 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	746030	Tenoretic 50 Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	866842	Atenolol 25 MG / Metoprolol Tartrate 25 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	199717	Clopidamide 5 MG / Pindolol 10 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898342	Amlodipine 10 MG / Benazepril hydrochloride 20 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898346	Amlodipine 10 MG / Benazepril hydrochloride 40 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898350	Amlodipine 2.5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898353	Amlodipine 5 MG / Benazepril hydrochloride 10 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898356	Amlodipine 5 MG / Benazepril hydrochloride 20 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898359	Amlodipine 5 MG / Benazepril hydrochloride 40 MG Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898344	Lotrel 10/20 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898348	Lotrel 10/40 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898352	Lotrel 2.5/10 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898355	Lotrel 5/10 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898358	Lotrel 5/20 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	898361	Lotrel 5/40 Oral Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858618	Enalapril Maleate 5 MG / Felodipine 2.5 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858621	Enalapril Maleate 5 MG / Felodipine 5 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858884	Lexxel 5/2.5 Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	858892	Lexxel 5/5 Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	854993	Indapamide 1.25 MG / Perindopril Erbumine 4 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389180	Felodipine 2.5 MG / Ramipril 2.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389181	Felodipine 5 MG / Ramipril 5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897781	trandolapril 1 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897778	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897783	trandolapril 2 MG / verapamil hydrochloride 180 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	901451	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Capsule
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897786	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897844	trandolapril 2 MG / verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897847	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897853	trandolapril 4 MG / Verapamil hydrochloride 240 MG 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897856	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897782	Tarka 1/240 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897785	Tarka 2/180 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897846	Tarka 2/240 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897855	Tarka 4/240 24 HR Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897780	trandolapril 1 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 1/240]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897787	trandolapril 2 MG / Verapamil hydrochloride 180 MG Extended Release Tablet [Tarka 2/180]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897848	trandolapril 2 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 2/240]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	897857	trandolapril 4 MG / Verapamil hydrochloride 240 MG Extended Release Tablet [Tarka 4/240]
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999986	Amlodipine 10 MG / Hydrochlorothiazide 12.5 MG / Olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999991	Amlodipine 10 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet

**PCPI eSpecification  
ADULT KIDNEY DISEASE  
AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730861	Amlodipine 10 MG / Olmesartan medoxomil 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730866	Amlodipine 10 MG / Olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999967	Amlodipine 5 MG / Hydrochlorothiazide 12.5 MG / Olmesartan medoxomil 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999996	Amlodipine 5 MG / Hydrochlorothiazide 12.5 MG / Olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1000001	Amlodipine 5 MG / Hydrochlorothiazide 25 MG / Olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730869	Amlodipine 5 MG / Olmesartan medoxomil 20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	730872	Amlodipine 5 MG / Olmesartan medoxomil 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744624	Azor 10/20 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744628	Azor 10/40 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744632	Azor 5/20 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	744636	Azor 5/40 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999971	Tribenzor 20/5/12.5 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999990	Tribenzor 40/10/12.5 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	999995	Tribenzor 40/10/25 (olmesartan medoxomil / amlodipine / HCTZ) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1000000	Tribenzor 40/5/12.5 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1000005	Tribenzor 40/5/25 (olmesartan medoxomil / amlodipine (as amlodipine besylate) / HCTZ) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876514	Amlodipine 10 MG / telmisartan 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876519	Amlodipine 10 MG / telmisartan 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876524	Amlodipine 5 MG / telmisartan 40 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876529	Amlodipine 5 MG / telmisartan 80 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876518	Twynsta 40/10 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876528	Twynsta 40/5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876523	Twynsta 80/10 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	876533	Twynsta 80/5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011718	aliskiren 150 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011729	aliskiren 300 MG / valsartan 320 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722126	Amlodipine 10 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722131	Amlodipine 10 MG / valsartan 320 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722134	Amlodipine 5 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	722137	Amlodipine 5 MG / valsartan 320 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848131	amlodipine 10 MG / HCTZ 12.5 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848151	amlodipine 10 MG / HCTZ 25 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848135	amlodipine 10 MG / HCTZ 25 MG / valsartan 320 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848140	amlodipine 5 MG / HCTZ 12.5 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848145	amlodipine 5 MG / HCTZ 25 MG / valsartan 160 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011735	Valturna (aliskiren 300 MG / valsartan 320 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	1011724	Valturna (aliskiren 150 MG / valsartan 160 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848149	Exforge HCT 5/160/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848144	Exforge HCT 5/160/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848139	Exforge HCT 10/320/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848155	Exforge HCT 10/160/25 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	848134	Exforge HCT 10/160/12.5 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724879	Exforge 10/160 Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724895	Exforge (amlodipine 5 MG / valsartan 320 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724891	Exforge (amlodipine 5 MG / valsartan 160 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	724887	Exforge (amlodipine 10 MG / valsartan 320 MG) Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	833237	Diltiazem Hydrochloride 180 MG / Enalapril Maleate 5 MG Extended Release Tablet



**PCPI eSpecification**  
**ADULT KIDNEY DISEASE**  
**AKID-1 : Blood Pressure Management**

Value Set ID	Clinical Topic	Topic Indicator	Measure Component	Standard Concept	Standard Category	Taxonomy	Code	Code Descriptor
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	846148	Teczem Extended Release Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389180	Felodipine 2.5 MG / Ramipril 2.5 MG Oral Tablet
000297	AKID	1	N	Multi Agent Anti-Hypertensive	Medication	RxNorm	389181	Felodipine 5 MG / Ramipril 5 MG Oral Tablet